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i 
ABSTRACT
 
The race to uncover new biological drug targets has led to an emerging field of 
research on the thermodynamic properties that stabilize transmembrane proteins as well
as the role of these stabilizing factors in shaping the evolutionary landscape of drug target
populations. When proteins are inserted into the plasma membrane, they fold into three-
dimensional secondary protein structures called alpha helices. The electrical interactions 
within the alpha helix causes the protein to form a macrodipole. As a result of this 
phenomenon, the energetic stabilities of TM proteins may either be disrupted or enhanced
due to the interactions between the surrounding membrane potential and the charged
dipole termini of the folded helix. Currently, the relative contributions of compensatory
factors to TM protein stability and their population distributions are poorly understood. In
this study, two categories of bitopic proteins and the hydrophobic energies of their TM 
domains were investigated. We hypothesized that Type I TM proteins exhibit lower
hydrophobic free energies as a compensatory response to the decreased electrical
stabilities of Type I proteins that have incurred an energetic penalty due to the spatial
orientations. A Z test showed that Type I proteins exhibit significantly lower hydrophobic 
free energies than Type II proteins (p = Į = 0.05). A Z test of Shannon entropies
of both protein types revealed that Type 1 proteins exhibit significantly lower Shannon 
entropies than those of Type 2 (p = 0.000, Į = 0.05). Linear regression analysis showed a
weak correlation between Type I Shannon entropies and Type I hydrophobic energies (R2
= 0.221) and Type II Shannon entropies and Type II hydrophobic energies (R2 = 0.232),
 
suggesting that Shannon entropies are not a direct function of hydrophobic free energies 
and may arise from synergistic interactions among various energetic contributors.
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Chapter I
INTRODUCTION
Natural selection is the primary mechanism that is hypothesized to govern 
evolutionary processes, and evolutionary outcomes are theorized to be constrained by the 
criteria of achieving increased fitness. Yet, differences in the persistence of populations, 
and their resulting sizes can also be explained by the necessity to conform to the 
thermodynamic principles that govern energy infrastructures within biological systems.
The direction of evolution is driven by the minimization of the total Gibb’s free energy in 
a system. This minimal energy criterion is contingent upon the second law of 
thermodynamics, which favors entropy maximization (Jia, Liggins, & Chow, 2014).
Disparities in thermodynamic fitness, which may arise from interactions among various 
factors including environment and phenotype, can prompt adaptive responses from other
components within a system in order to maintain overall thermodynamic stability.
If the evolutionary constraints exerted upon the system persist and are quite
strong, compensatory responses may also be conserved over time within a population.
One example of a molecular system that is not exempt from the principle of minimal 
energy is membrane proteins. The unfavorable interactions between the termini of 
membrane protein dipoles and their electrically charged environments may be recognized
by protein selection and insertion machinery (Agnati et al., 2005). As a result, proteins 
with greater stabilizing characteristics, such as high hydrophobic energies, may be
selected for insertion within the hydrocarbon cores of cellular membranes in order to
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compensate for their otherwise high instabilities. However, few studies have investigated
this hypothesis.
Understanding the thermodynamics underlying membrane protein stability is 
desirable for many reasons. Membrane proteins account for roughly one-third of all
sequenced proteins and are one of the most important features of cellular systems (Hubert 
et al., 2010). These proteins play diverse roles in the normal functioning of cells and are
involved in various functions, including cell-cell adhesion, molecular transport, ion 
regulation, signal transduction, enzyme catalysis, and immune pathways. Since 
membrane proteins are key components of cellular defense pathways, a fundamental
understanding of the thermodynamic mechanisms underlying their stability and
functioning is essential to drug development initiatives. In fact, bitopic membrane 
proteins account for more than 60% of all known drug targets encoded by the human 
genome (Yin & Flynn, 2016).
Currently, most exogenous agonists are designed to inhibit, activate, or modify
cell signaling pathways by selectively binding to protein moieties acting as cell-surface
receptors and subsequently triggering or suppressing associated effector and second
messenger cascades. Therapeutic ligands are designed to adhere exclusively to exposed
peptide regions that are easily accessible on the surface of the bilayer. In fact, G-protein 
coupled receptors account for one-third of drug targets (Dror et al., 2011). Yet, 
therapeutic agents are seldom designed to directly target transmembrane domains 
embedded deep in the interior of the hydrophobic bilayer.
The tendency to develop therapeutics that target exposed protein segments instead
of those that target protein segments embedded within the bilayer’s hydrophobic core can
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be attributed to several factors. First, the process of accessing the hydrophobic core of
the plasma membrane is experimentally complex and often difficult to achieve. Steroids 
and small nonpolar molecules characterized by high permeability are able to passively
diffuse across the transmembrane region of the bilayer, but the passage of the majority of
large polar molecules involves transport-mediated or endocytic pathways. Although not 
altogether impossible, the translocation of proteins and small peptides across membranes
is rare (Yang & Hinner, 2016). Another perceived barrier to the viability of 
transmembrane drug targets is that drug targets require high specificity, but it is still
unknown which specific regions of the transmembrane region could serve as potential
drug targets.
Second, the erroneous concept that transmembrane domains serve no other
purpose than to anchor the protein within the bilayer is, unfortunately, quite prevalent. 
The idea that transmembrane domains do not engage in meaningful interactions that are
subject to drug targeting still informs much of the development of biopharmaceuticals. 
This notion is gradually changing as experimental evidence is accumulating that shows 
the functional importance of transmembrane domains. Nevertheless, the properties of 
transmembrane domains involved in disease pathways has remained relatively
underexplored compared to the attention that has been paid to their extracellular
counterparts.  Experiments examining the extent to which the hydrophobicities of 
transmembrane helices serve as an energetic hindrance to retrotranslocation by
endoplasmic reticulum associated degradation (ERAD) pathways during protein 
misfolding have been performed, but information regarding the general mechanism and
details underlying transmembrane domain removal from the bilayer preceding
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degradation is scarce (Guerriero et al., 2017).  Exacerbating the inattention to 
transmembrane drug targets is the dearth of available information on membrane protein 
three-dimensional structure (Opella & Marassi, 2004). In fact, only 2% of structures in 
the Protein Database Bank belong to membrane proteins (Zhou, Zheng, & Zhou, 2004). 
Ultimately, the reality remains that the number of available extracellular drug targets 
encoded by the human genome is finite. When pharmacotherapy has exhausted the study
of extracellular drug targets, the pressure and the demand for the study and identification
of novel drug targets and their biophysical properties will inevitably increase.
In spite of the biases underlying drug research, the advancement of existing and 
novel biotechnological methods is helping to redefine the notion of what makes
molecular moieties targetable. Advances in X-ray crystallography, cryoelectron 
microscopy, and nuclear magnetic resonance spectroscopy are contributing to the 
growing database of available membrane protein structures and protein-protein
interactions and could greatly help to inform structure-based rational design (Punta et al.,
 
2007). The refinement of ToxR, an experimental method that probes interactions among 
transmembrane domains, is another promising advancement in the quest for information 
on transmembrane domain interactions. In addition, the discovery of highly specific and
localized protein-protein interaction hot spots has encouraged the development of drugs
that exclusively target these critical areas. The novel synthesis of molecular mimics that
influence transmembrane domain-domain interactions also represents an alternative 
method of drug delivery. For example, small molecules have been identified that target
Toll-like Receptor one and two, a key player in Parkinson’s disease.
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In light of the evolving definition of what constitutes a good drug target and the 
rapid pace of biotechnological development, research on the fundamental properties of 
transmembrane domains is essential. It is incumbent upon the scientific community to 
ensure that the availability of information on transmembrane domains and the 
interactions among them progresses at a rate equal to that of biotechnological advances. 
In anticipation of the emerging need for more information on the physicochemical
properties of transmembrane domains, we performed a comparative study that
characterizes the stabilizing properties of transmembrane proteins, namely the 
hydrophobic free energies of their hydrophobic domains. In this study, we identified
statistical differences between the hydrophobic free energies and Shannon entropies of 
two groups of bitopic proteins. A weak correlation between hydrophobic free energies
and Shannon entropies was determined, and further research is needed in order to 
elucidate the precise mechanisms underlying the correlation between these two 
parameters.
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Chapter II
 
REVIEW OF LITERATURE
 
Type I and Type II Proteins
 
Membrane proteins are proteins that are embedded in the plasma membrane, a 
lipid bilayer that serves as a selectively permeable barrier between the interior cellular 
environment and the surrounding extracellular space. Two classes of membrane proteins 
are peripheral and integral membrane proteins. Peripheral membrane proteins are water-
soluble proteins that are attached to the exterior surface of the plasma membrane, while 
integral membrane proteins are proteins that have one or more regions embedded in the 
hydrophobic core of the lipid bilayer. Integral membrane proteins that have backbones
that transverse the entire length of the phospholipid bilayer are called transmembrane 
proteins (Cooper, 2000). Transmembrane proteins consist of bitopic and polytopic
proteins. Bitopic proteins cross the bilayer only once. Examples of bitopic proteins 
include Type I, Type II, and Type III proteins. Polytopic proteins, such as Type IV
proteins, cross the bilayer more than once (Zviling, Kochva, & Arkin, 2007).
Type I and Type II TM proteins are polymers composed of individual monomeric 
amino acid units held together by peptide bonds. They typically exist as a distinct type of 
secondary structure protein called an alpha helix and assume the three-dimensional shape 
of a coil or a screw that is held together by hydrogen bonds (Albers, 1999). In terms of 
chirality, most alpha helical proteins are right handed (Cole & Bystroff, 2009). Type I
membrane proteins are characterized by a signal peptide sequence that is approximately
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15 hydrophobic amino acid residues in length and is subsequently cleaved from the rest 
of the peptide. The signal that cues the protein to remain embedded in the membrane 
instead of being completely threaded through is called a stop-transfer sequence, which is 
composed of approximately 20 hydrophobic amino acid residues. The signal peptide 
sequence and the stop transfer sequence result in the translocation of the peptide’s N-
terminus across the membrane.
In contrast to Type I membrane proteins, Type II membrane proteins contain a 
signal-anchor sequence that is approximately 25 hydrophobic amino acid residues in 
length and are much longer than Type I signal sequences. Type II signal-anchor 
sequences are characterized by the absence of a signal peptidase cleavage site and are
therefore not cleaved after translocation occurs. Type II signal-anchor sequences result in 
the translocation of the peptide’s C-terminus across the membrane. Type I proteins have 
their positively-charged amino group oriented towards to the extracellular space while 
their negatively-charged carboxyl groups are oriented towards the cytoplasmic interface.
Type II proteins have their negatively-charged carboxyl groups oriented towards the 
extracellular space, while their positively-charged amino groups are oriented towards the 
cytoplasmic compartment. Thus, Type I and Type II proteins are opposites of each other
in terms of their orientations within the membrane (Goder & Spiess, 2001).
The Alpha Helix Dipole
 
Peptide bonds within Type I and Type II proteins produce individual dipoles. Each 
protein has a net dipole moment with two polarized termini that is calculated from the
sum of the individual dipole moments of peptide bonds (Moran, Horton, Scrimgeour, & 
Perry, 2011). A dipole moment is a vector value that quantifies and describes the
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electrical polarity of a molecule. A dipole moment is formed when a molecule contains 
atomic regions that possess a partial positive or partial negative charge and are spatially
arranged in such a way so that they do not cancel one other out. Electronegativity is a 
measure of an atom’s affinity for electrons in a bond, and unequal charge distributions in 
a molecule arise due to differences in the electronegativities of the individual atoms 
comprising that molecule. Dipole moments can occur in both diatomic and polyatomic 
molecules. In a diatomic molecule containing two covalently bonded atoms possessing 
unequal electronegativities, the more electronegative atom will attract electrons 
(negatively charged particles) to itself and acquire a partial negative charge, while the 
less electronegative atom will acquire a partial positive charge. In general, a dipole
moment can be calculated using the following equation: μ=q x r, where μ is the size of 
the dipole moment, q is the charge, and r is the distance of separation between the two 
charges. The unit symbol of a dipole moment is D, which stands for units of Debye. In
artistic renderings, the dipole moment can be drawn as an arrow with a cross tail. While
many chemistry textbooks render the tip of the arrow to denote the negative pole and the 
crossed tail to denote the positive pole, physics conventions use IUPAC nomenclature 
and represent the tip of the arrow as the positive pole and the crossed tail as the negative 
pole (Parkanyi, 1998).
Proteins are composed of amino acids joined by a peptide bond, a type of covalent 
bond.  Each amino acid is composed of an alpha carbon, a hydrogen, a unique side chain 
residue, an amino group (-NH2), and a carboxyl group (-COOH). A dehydration
synthesis reaction produces a peptide bond between two individual amino acids and 
releases a water molecule. At physiological pH, amino acids exist as zwitterions, and
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their structures are represented differently from their representations in theoretical
reactions, but the process is relatively the same. In the theoretical condensation reaction,
the lone pair of electrons on the nitrogen of the amino group will perform a nucleophilic
attack on the carbon of the carboxyl group. As a result, the pre-existing lone pair of 
electrons on the nitrogen will form a new bond between the amide nitrogen and the 
carbonyl carbon. This results in carbon having 10 valence electrons, which violates the 
octet rule, which leads to the hydroxyl (-OH) that comprises the carboxyl group on the 
first amino acid being protonated when it binds to a hydrogen in the amino group of the 
second amino acid. The -OH will remove the two electrons it originally shared with 
carbon and use them to form a bond to a hydrogen of the second amino acid. The 
combination of -OH and -H forms a water molecule. The lone pair of valence electrons 
that is left by the hydrogen may either: continue to exist as a lone pair on the nitrogen or 
form a second bond between the nitrogen and the carbon, which creates partial double
bond character to the N-C of the peptide bond; this delocalization of electrons is called
resonance. Apart from the structural stability that it confers to a peptide bond, resonance
paradoxically also confers stereochemical variation. Since the amide nitrogen’s electrons 
are delocalized, the dipeptide segment is a stereoisomer that can assume one of two
isomeric forms (cis- or trans-) in three-dimensional space. The cis- isomer is when the 
functional groups are on the same side, while the trans- isomer is when the functional
groups are on opposite sides. At physiological conditions, the majority of dipeptide 
segments exist in the trans- form. When dipeptide segments exist in a trans orientation, 
the arrangement of atoms permits a dipole to form.
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A peptide bond’s dipole moment is due to differences in electronegativity between
two pairs of atoms. The first pair of atoms is the oxygen and the carbon in the amino
acid’s carbonyl group.  Since oxygen’s electronegativity is greater than that of carbon,
the oxygen will assume a partial negative charge (-0.42) and the carbon will assume a
partial positive charge (+0.42). The second pair of atoms is the nitrogen and the 
hydrogen in the amino acid’s amino group.  Since nitrogen’s electronegativity is greater
than that of hydrogen, the nitrogen will assume a partial negative charge (-0.20) and the 
hydrogen will assume a partial positive charge (+0.20). Both dipole moments formed by
each pair of atoms exist parallel to the helix axis. In addition, the alpha helix contains 
three types of torsional angles: Ȧĳ, and ȥ.  Ramachandran plots are plots of the ĳ (phi) 
angles against WKHȥ (psi) angles; the presence of clusters indicates that a helix possesses 
a regular repeating structure. Since Ramachandran plots indicate that the ĳ aQGȥ angles
of each amino acid in a helix are very similar (-57º and -47º, respectively), the alpha helix
exhibits structural regularity. Structural regularity is vital to preventing the disruption of
a helix’s net dipole moment.  Since the alpha helix is composed of 3.6 residues per turn
and contains multiple repeating turns depending on its length, it contains multiple peptide 
bonds. The individual dipole moments of each peptide bond will result in a net dipole 
moment called a macrodipole with charged terminal ends, where the amino terminus is 
positive and carboxyl terminus is negative. Since the dipole moment of a single peptide 
bond is 3.6 D, the macrodipole of an alpha helix can be calculated as the number of
amino acid residues times 3.6 D.
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Electrical Properties of Cellular Membranes
 
Cellular systems are characterized by the presence of an electrical gradient at the 
membrane boundary. These electrical gradients confer a positive charge along the 
membrane-extracellular space (ECS) interface and a negative charge along the 
membrane-cytoplasm interface. This electrical gradient is called membrane potential, 
which is analogous to an electromagnetic field. When magnetic dipoles are placed in 
electric fields, their energetic stability may be high or low. Similarly, when TM proteins 
are placed within membranes having membrane potential, their energetic stabilities may
be disrupted or enhanced due to the interactions between the voltage gradient and the 
charged dipole termini of native proteins (Figure 1).
 
Figure 1. Schematic of protein macrodipole in membrane field potential
 
 
 
 
The difference in the orientations of Type I and Type II membranes suggests that 
there is also a difference in electrical energy between these two transmembrane proteins. 
Type I proteins may exhibit greater thermodynamic instability due to the interactions 
between their negatively-charged carboxyl groups and the negatively charged membrane-
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cytoplasm interface. Type II proteins may exhibit less thermodynamic instability due to 
the interactions between their positively-charged amino groups and the positively-
charged membrane-ECS interface. This observation is based on Coulomb’s law, which
simply states that oppositely charged particles tend to attract, while similarly charged
particles tend to repel. These principles are illustrated by potential energy curves, which
demonstrate that as the distance between like-charges decreases (as they move closer
together), their repulsive potential energy increases; however, as the distance between
opposite charges decreases (as they move closer), their repulsive potential energy
decreases.
It is possible to measure the strength of attractive and repulsive forces using
Coulomb’s law, which measures the strength of the force/energy between a pair of 
charges in joules (J). Attractive forces are indicated by negative signs (gained by the
product of two opposite charges), while repulsive forces are indicated by positive signs (a 
result of the product of two similar charges). In the following formula, k is a constant of
2.31 x 10-19 J ÂQP Q1 and Q2 represent the quantities of the charges on each respective
 
particle, and r is the distance between the two atoms:
 
kQ1Q2
F=
r2
 
The degree of a force (whether attractive or repulsive) between two atoms is the product
of the two charges on both atoms divided by measure of the distance between them 
multiplied by the constant, k. Thus, as a result of this biophysical dynamic, Type I
proteins may exhibit greater electrochemical instability. The former situation results in 
greater thermodynamic stability, while the latter situation results in lower thermodynamic
instability. Since the configurations of Type I proteins represent the latter situation, they
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are, in effect, at a greater energy disadvantage due to their orientation within cellular 
membranes.
Determinants of Protein Stability
 
The properties of lipid bilayers that surround membrane proteins are one of the 
determinants of membrane protein stability are the properties of the lipid bilayers that 
surround membrane proteins (Van Klompenburg, Nilsson, von Heijne, & de Kruijff,
1997).  Unlike the substances that solvate globular proteins, the lipid medium is far from 
isotropic. The plasma membrane is composed of a variety of different lipids, and certain 
types of lipids are more abundant in certain areas of the bilayer. For example, the 
extracellular outer leaflet usually contains high amounts of sphingolipids, glycolipids, 
and phosphatidylcholine, while the cytoplasmic inner leaflet usually contains 
phosphatidylserine, phosphatidylethanolamine, and phosphatidylinositol. Some lipids, 
such as cholesterol, are evenly distributed throughout both layers and may cause 
fluctuations in the permeability of the membrane. Such disruptions to membrane
permeability may influence protein stability. The disparities in regional lipid composition 
along a membrane may primarily be attributed to the presence of lipid rafts. Lipid rafts 
are lipid-dense areas along the plasma membrane that contain localized and unique 
concentrations of sphingolipids, cholesterol, and proteins (Pike, 2003). The ability of 
components to be recruited to or disassociate from lipid rafts and the ability of rafts to 
move laterally and combine with other rafts (in a process called raft clustering) make the 
lipid composition of these areas highly dynamic.
The high variety of lipids that comprise membranes may be due to the 
corresponding diversity of proteins that they solvate and the interactions that occur
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between them amidst fluctuations in temperature, osmolarity, pH, and supramolecular 
lipid polymorphisms (Simons & Sampaio, 2011). A membrane protein’s ability to 
function depends on the presence of particular lipids having specific head groups or
hydrocarbon tails that may serve to optimize its functionality (Deol, Bond, Domene, &
Sansom, 2004). Furthermore, the chemical composition of a lipid membrane encasing a 
particular organelle may be very different from those of other organelles. Studies have 
also found that the electrostatic properties of membrane voltage gradients are dependent 
upon the compositions of the lipids that generate them (Gurtovenko & Vattulainen, 2008).
Similarly, the lengths of lipids that comprise the membrane help determine the thickness
of the phospholipid bilayer (Lee, 2004).  On average, the polar headgroups of lipids are
15 Å, and their hydrophobic regions are 30Å (Haltia & Freire, 1995). Yet, differences in 
lipid composition in certain regions of the bilayer may result in variations in membrane 
thickness along the circumference of the cell (Nagle & Tristram-Nagle, 2000). It has
been shown that fluctuations in temperature may affect lipid thickness as well (Simon,
Advani, & McIntosh, 1995).
Apart from influencing the electrostatic gradients across membranes, variations in
the thickness of the bilayer are important, since it may also affect the angle at which a 
membrane protein is tilted perpendicular to the membrane plane (Kim & Im, 2010). 
Multiple studies have shown that when bilayer thickness is shortened, protein tilt angle
— the angle formed by the protein and the axis perpendicular to the membrane plane —
increases (Holt et al., 2009). The biological phenomenon in which a discrepancy exists
between the length of the transmembrane helix and membrane thickness is called
hydrophobic mismatch (de Jesus & Allen, 2013). Changes in tilt angle in response to the
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shortening of the bilayer occur in order to optimize the retention of the peptide’s
transmembrane helix and hydrophobic residues within the hydrophobic core (Park &
Opella, 2005). In addition, it has also been observed that helices may bend and stretch in 
response to hydrophobic mismatch (de Jesus & Allen, 2013).
Hydrophobicity Scales
 
Hydrophobicity is a quantitative measure used to determine how anchored a 
protein is within the membrane. Hydrophobicities are represented as GRAVY values and
are computed as the average of the hydrophobicities of each amino acid within a 
polypeptide sequence. A hydrophobicity scale assigns a hydropathy value to each of the
20 amino acids. Several hydrophobicity scales are available, and each scale is 
constructed using different methods. The Kyte and Doolittle (KD) hydrophobicity scale
is one of the most widely used hydropathy scales in the field of biophysics (Appendix A).
In the Kyte and Doolittle scale, the majority of the hydropathy values for each individual 
amino acid were determined by averaging two or three normalized values (Kyte &
Doolittle, 1982). The first value is the transfer free energies from water to vapor
ǻG°waterĺ vapor) in kcal/mol. This value was used in lieu of the transfer free energies 
from water to ethanol and ethanol to vapor, due to the non-neutral properties of ethanol. 
The water-vapor transfer partition coefficients were based on model substances
equivalent to each amino acid residue and represent a compilation of data collected by
scientists including Hine and Mookerjee (1975) and Wolfenden, Cullis, & Southgate 
(1979).  Chothia (1976) used twelve globular native structures and their coordinates to 
record the number of times a particular amino acid residue was found to be 95% buried
within the interior of the protein. This value was then divided by the total number of that
16
 
occurring residue. Thus, the second value is the fraction of residues that are 95% buried,
and the third value is the fraction of residues that are 100% buried.
Functional Significance of Transmembrane Domains
 
Apart from securing membrane proteins in the bilayer, transmembrane domains 
play many important roles in the biological and biochemical functions of proteins 
involved in disease pathways. For example, mutations in the third transmembrane 
domain of the melanocortin-4 receptor (MC4R) – a G protein-coupled receptor, that has
been identified as a cause of obesity – significantly affect ligand binding, signaling, and
second messenger production (Mo, Yang, & Tao, 2012). Similarly, experiments have 
shown that transmembrane domains of a viral membrane protein called LMP-1 are 
primarily involved in signaling activity of the Epstein-Barr virus (Kaykas, Worringer, &
Sugden, 2002). It has been found that mutations in transmembrane domains of the 
diphtheria fusion protein toxin DAB3890-IL-2 can alter cytotoxicity (VanderSpek,
Mindell, Finkelstein, & Murphy, 1993).  Mutations in transmembrane domains of 
penicillin binding proteins in S. pneumoniae have given rise to morphological
modifications in cells, which shows the importance of transmembrane domains in
peptidoglycan construction (Berg et al., 2014).  Furthermore, the transmembrane domains 
of a kidney-lung sodium channel complex are responsible for indicating degradation by
endoplasmic reticulum chaperones (Buck et al., 2017). In addition, transmembrane 
domains have also been found to facilitate the dimerization of toll-like receptor (TLR)
proteins (Godfroy, Roostan, Moroz, Korendocych, & Yin, 2012).  Other scientists have 
found that survival proteins mediate apoptosis inducing proteins, such as Bax, through
transmembrane domain mediated associations (Andreau-Fernandez, 2017).
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Transmembrane domains are also known to influence the energetic interactions 
within cells. The transmembrane domain of the Influenza A viral M2 proton channel is
responsible for proton translocation (Hu et al., 2007). Transmembrane domains also have 
biophysical implications on the characteristics of membrane proteins. For example, the 
macrodipole of transmembrane proteins significantly contributes to the ability of proteins 
to participate in helix-bundle aggregation and their transport capabilities. Helices that 
comprise a bundle are often positioned antiparallel to one another due to the increased
stabilization that is conferred. In turn, aggregation and orientation can greatly influence
the variable functional capabilities of the membrane proteins and those of the aggregates 
that they form (Brady, Siegel, Albers, & Price, 2012).  Hence, transmembrane domains
are involved in lateral associations that may result in oligomerization and protein-protein 
interactions (PPIs).
18
 
 
 
 
 
 
Chapter III
 
MATERIALS AND METHODS
 
Data Collection
 
Retrieval of Type I and Type II Protein Accession Numbers
 
Type I and Type II membrane proteins and their accession numbers were retrieved
from UniProtKB (http://www.uniprot.org). Lists for all Type I and Type II proteins were 
located by setting the filter function to display proteins by “subcellular location” and
inputting “single-pass” in the search bar on the database’s home page.  Proteins were 
sorted by type and stored in Excel spreadsheets. Only proteins that were Swiss-Prot 
manually annotated and reviewed (via experimental research or computerized prediction 
models) were selected in order to maintain quality assurance. Proteins found in
organisms other than Homo sapiens were excluded from this study. Only proteins 
residing in the plasma membrane were retained.
Retrieval of Transmembrane Domain Residue Sequences
 
Amino acid sequences comprising the transmembrane regions of all Type I and
Type II alpha helical proteins were individually retrieved from each of the protein profiles
contained in UniProtKB. Retrieval was accomplished by accessing a particular protein’s
profile and selecting the “Subcellular Location” tab on the leftmost menu bar shown on 
the subsequent interface. The residue sequence was obtained by locating the
“Position(s)” column and selecting the range of position numbers displayed adjacent to
the “Transmembrane” row in the “Feature Key Table” that is included in the “Topology”
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subsection of the protein’s profile. All residue sequences were transferred to Excel
spreadsheets and stored alongside their corresponding accession numbers.
Retrieval of Grand Average of Hydropathicity Values
 
Manually computed Grand Average of Hydropathicity (GRAVY) values were 
validated externally using the integrative ProtParam software tool from the SIB ExPASy
(Expert Protein Analysis System) Bioinformatics Resource Portal. This is a
supplementary portal that can be accessed from within the UniProtKB database. Within 
any given protein profile, the “Sequence” tab was selected from the left menu bar and the 
“ProtParam” option was selected from the dropdown menu bar. The range for a sequence
fragment corresponding to “FT TRANSMEM” was selected.  Only peptide sequence
fragments with endpoints designated “TRANSMEM” were selected for physicochemical
properties analysis. The GRAVY value was obtained by locating the computed parameter
on the protein analysis interface. ExPASy ProtParam GRAVY values were matched
against computed values (based on the same Kyte-Doolittle hydropathy scale) in order to 
identify errors and inconsistencies in computed values.
Retrieval of Kyte and Doolittle Hydropathy Indices
 
The Kyte and Doolittle hydropathy indices for all amino acids were obtained by
accessing the ExPASy portal’s ProtScale tool (http://www.expasy.org) and selecting the 
“Hphob. / Kyte & Doolittle amino acid scale” from the list of available scales.  Each
amino acid’s hydropathy index was imported into Excel. Hydropathy values were 
validated by directly accessing the original article.
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Retrieval and Determination of Protein Functional Class
 
Functional classes of all proteins were determined by accessing a particular
protein’s profile and selecting the “Function” tab on the leftmost menu bar shown on the 
interface of each individual UniprotKb protein profile. All known molecular and
biological functions of each protein were retrieved from the “Function” subsection.
Enzymatic functions and pathways were retrieved from Reactome, a peer-reviewed
external database that can be accessed through UniprotKb (http://www.reactome.org). 
Proteins were classified into one or more of the following functional categories: Enzyme,
Receptor, Both Enzyme and Receptor, Immune, Both Immune and Receptor, Transporter,
and Other. The function(s) of proteins belonging to the category “Other” were recorded
in a separate column.
Mathematical Computation
 
Computation of Gibb’s Free Energy
 
The electrical free energies ǻG°) of the dipoles of Type I and Type II alpha
helices in the charged membrane field were calculated using the electrical free energy
equation: ǻG = μE where μ is the dipole moment charge (1 electron) multiplied by the 
electron charge (1.6 x 10-19 C) multiplied by the length of the helix (Lh).  E is the 
membrane potential (Vm) divided by the thickness of the membrane (Lm). Here, we make 
the following assumptions: 1) The length of each helix approximates the thickness of the 
portion of the membrane it is embedded in, 2) membrane potential is 100 mV.
Computation of Hydrophobic Energies
Following residue sequence retrieval, the hydrophobicity values of all Type I and
 
Type II proteins were manually calculated using UniprotKb. Sequences were
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manipulated in Excel and treated as text strings. Alphabet characters comprising each
text string sequence were horizontally divided into individual cells. The “text to
columns” feature was used to set field widths and create column breaks so that a single 
letter representing a single amino acid was assigned to a solitary cell. Subsequently,
individual hydropathy indices for all 20 amino acids based on the Kyte-Doolittle scale 
(Appendix A) were imported from ExPASy and assigned to their corresponding amino
acid symbol in Excel. All amino acids were replaced with their corresponding scale
values using the “substitution” feature.  GRAVY values for all proteins were calculated as
the average (the sum of the hydropathy values of all constituent amino acids divided by
the number of residues in the sequence) of each alpha helix’s amino acid constituents. 
GRAVY values were then multiplied by the number of amino acid residues in each
protein’s transmembrane domain. GRAVY values were converted from units of kcal/mol 
to units of kJ/mol.
Computation of Shannon Entropies
 
Information entropies of both groups of transmembrane proteins were determined
and compared. The following formula was used to compute Shannon entropies (SE): SE
= -ȈPlog2P, where P is the probability of a given amino acid within a given protein’s
residue sequence. Amino acid text sequences were converted to columns and column
breaks were inserted. The “substitution” feature was used to replace each amino acid 
letter symbol with the number 1, and the “=SUM” formula was used to compute the 
number of times an amino acid appeared within a given sequence. Once the frequency of 
appearance was calculated, the 1s were replaced with the amino acid letter symbol once 
more. As a precautionary measure, the number zero was used to replace all ones in order
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to ensure that if ones were not replaced with their amino acid letter symbol for any
reason, that the retained ones would not affect the subsequent frequencies of the next
amino acid being summed. This procedure was performed for all 20 amino acids for all
proteins. Once the frequencies of all amino acids were calculated, the lengths of each
sequence was calculated using the “=LEN(first cell, last cell)” formula. The probability
value of each amino acid was computed by dividing the amino acid frequencies by the
length of the entire protein. In order to achieve this, the conditional formula function
“=IF(probability = 0, 0, probability *(LOG(probability, 2)))” was used. Following this
step, the “pLog2P” amino acid values for each row were summed to yield the Shannon
entropies of each transmembrane protein.
Statistical Analysis
 
Monte Carlo Simulation of Normal Distribution of Hydrophobic Energies
 
A random number generator in Excel was used to generate 10,000 random 
transmembrane amino acid residue sequences. Hydrophobic energies for each sequence
was calculated, and a frequency distribution of all sequence hydrophobic energies was
created in order to ensure that the hydrophobic energies of the random sequences were 
normally distributed.
Shapiro Wilk Test of Gaussian Normality of Hydrophobic Energies
 
In order to determine if the assumption of normality required by the Student’s t 
test were met by the data, Statistical Package for the Social Sciences (SPSS) software 
was used to perform a Shapiro Wilk test. Both Type I and Type II proteins along with 
their respective hydrophobic energies were transferred to a new data sheet in SPSS. The 
“Analyze” tab was selected from the top menu bar, and the “Explore” function was
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selected. Type was moved to the “Factor List” space and Hydrophobic Energy was
moved to the “Dependent List.” The “Statistics” tab was opened and used to set the 
“Confidence Interval for the Mean” to 95%. Only the “Descriptives” box was checked.
The “Plots” tab was opened and “Normality plots with tests” was checked. No changes
were made to the “Options” criteria. As a supplement to the Shapiro Wilk test, 
histograms showing the frequency distributions of both Type I and Type II protein 
hydrophobic energies were created in order to provide a secondary visual measure with 
which to assess the data. To create the histograms, Minitab software was used. The data
was transferred into a new spreadsheet, and the “Graphs” tab was used to generate the 
histograms.
Levene’s Test of Equality of Variances of Hydrophobic Energies
 
In order to determine if the assumption of equal variances required by the 
Student’s T test were met by the data, SPSS was also used to perform a Levene’s Test for 
homogeneity of variances. A Levene’s test for homogeneity of variances was conducted
using a “One-Way ANOVA” where default settings for “Contrasts” and Post Hoc 
Criteria” were used.
Mann-Whitney U Test of Hydrophobic Energies
 
Following the validation of the assumptions required by the parametric Student’s
T test, SPSS was used to perform a non-parametric Mann-Whitney U test in order to 
determine whether or not there exists a statistically significant difference between the 
hydrophobic energies of Type I and Type II protein groups. The “Analyze” tab was
selected from the top menu bar, “Nonparametric Tests and Legacy Dialogs” were 
selected, and a “2 Independent Samples Test” was performed. Test and grouping
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U -
variables were organized and each group was defined as one and two, respectively. In the 
“Options” criteria, “Descriptives and MWU” were selected.  Given n1=1118, n2=155, and 
the Sum of Ranks = 726967.50, the following formulas were used to derive the U test
statistics for the hydrophobic energies of both Type I and Type II proteins:
 
 
 
 
n (n +1) U =n n + 1   1 
 
- Sum of Ranks
1 1  2 2
 
U =n n - (U ) 
2 1  2 1
 
 
 
 
The value that was selected to be compared to the U-critical value is the smaller of U1
 
and U2; thus, U1 was retained.
 
Z Test of Hydrophobic Energies
In order to perform a Z test, the Z-test statistic of the hydrophobic energies was
derived using the following formula:
 
ξ(n n )(n +n +1)
Standard Deviation= 1 2     1    2 12
 
n n
12 2Z = 1
Standard Deviation
 
Monte Carlo Simulation of Normal Distribution of Shannon Entropies
 
A random number generator in Excel was used to generate 10,000 random 
transmembrane amino acid residue sequences. Shannon entropies for each sequence was
calculated, and a frequency distribution of all sequence Shannon entropies was created in 
order to ensure that the Shannon entropies of the random sequences were normally
distributed.
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Shapiro Wilk Test of Gaussian Normality of Shannon Entropies
 
In order to determine if the assumption of normality required by the Student’s T
test was met by the Shannon entropies of Type I and Type II proteins, SPSS software was
used to perform a Shapiro Wilk test. The “Analyze” tab was selected from the top menu 
bar, and the “Explore” function was selected. “Type” was moved to the “Factor List”
space and “Shannon Entropy” was moved to the “Dependent List.” The “Statistics” tab 
was opened and used to set the “Confidence Interval for the Mean” to 95%. Only the 
“Descriptives” box was checked. The “Plots” tab was opened and “Normality plots with 
tests” were checked. No changes were made to the “Options” criteria. As a supplement 
to the Shapiro Wilk test, histograms showing the frequency distributions of both Type I
and Type II protein Shannon entropies were created in order to provide a secondary
visual measure with which to assess the data.  Histograms were created using Minitab. 
Levene’s Test of Equality of Variances of Shannon Entropies
A Levene’s test of homogeneity of variances (SPSS) was used to determine if the 
assumptions of equal variances required by the Student’s T test was met by the Shannon 
entropies of Type I and Type II proteins. The “Analyze” tab was selected from the top 
menu bar, the “Compare Means” function was selected, and a “One-Way ANOVA” was
performed. No changes were made to the “Contrasts and Post Hoc criteria.” Under
“Options,” “Homogeneity of Variances” was selected.
Mann-Whitney U Test of Shannon Entropies
 
Following the validation of the assumptions required by the parametric Student’s
T test, SPSS was used to perform a non-parametric Mann-Whitney U test in order to 
determine whether or not there exists a statistically significant difference between the
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U –
Shannon entropies of Type I and Type II protein groups. The “Analyze” tab was selected
from the top menu bar, “Nonparametric Tests” and “Legacy Dialogs” were selected, and a
“2 Independent Samples Test” was performed. Test and grouping variables were 
organized and each group was defined as one and two, respectively. In the “Options”
criteria, “Descriptives and Mann-Whitney U test” were selected. Given n1=1118, n2=155,
and the Sum of Ranks = 690642.50, the following formulas were used to derive the U-
test statistics for the Shannon entropies of both Type I and Type II proteins:
 
 
 
 
n (n +1) U =n n + 1   1 
 
- Sum of Ranks
1 1  2 2
 
U =n n -(U ) 
2 1  2 1
 
 
 
 
The value that was selected to be compared to the U-critical value is the smaller of U1
 
and U2; thus, U2 was retained.
Z Test of Shannon Entropies
In order to perform a Z test, the Z-test statistic of the Shannon entropies was
 
derived using the following formula.
 
 
 
 
ξ(n n )(n +n +1)
Standard Deviation= 1 2     1    2 12
 
n n
12 2Z = 1
Standard Deviation
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Linear Regression of Hydrophobic Energies and Shannon Entropies
 
Shannon entropies of both Type I and Type II proteins were regressed against the 
transmembrane domain hydrophobic energies of both Type I and Type II proteins, 
respectively. Linear best fit lines and R2 values were generated for each regression plot.
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Chapter IV
 
RESULTS
 
Gibb’s Free Energy Difference
 
The Gibb’s free energy of Type I proteins was calculated to be 4.816 kJ/mol, and 
the Gibb’s free energy of Type II proteins was calculated to be -4.816 kJ/mol. The total
difference in electrical free energy (ǻǻG°) stability between and Type I and Type II 
proteins in the charged membrane field was calculated to be 9.63 kJ/mol using the 
following calculations:
ǻG° = μE
 
ǻGtype1° = [(0.5 e) x (1.6 x 10-19 C / 1 e) x (0.1V) x (6.02 x 1023/mol)] x (10-3 kJ/J)] 
ǻGtype1° = 4.816 kJ/mol
ǻGtype2° = -[(0.5 e) x (1.6 x 10-19 C / 1 e) x (0.1V) x (6.02 x 1023/mol)] x (10-3 kJ/J)] 
ǻGtype2° = -4.816 kJ/mol
ǻǻG° = ǻGtype1° - ǻGtype2° ǻǻG° =
4.816 kJ/mol – -4.816 kJ/mol ǻǻG° =
9.63 kJ/mol
Frequency Distributions of Hydrophobic Energies
 
Histograms were constructed to provide preliminary and alternative visual 
assessment of the frequency distributions of hydrophobic energies for both groups of
proteins (Figures 2 and 3). Type I mean hydrophobic energy was calculated to be 231.6 
kJ/mol, while Type II mean hydrophobic energy was calculated to be 217.1 kJ/mol.
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Figure 2. Frequency distribution of Type I TM protein hydrophobic energies
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Figure 3. Frequency distribution of Type II TM protein hydrophobic energies
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Mann-Whitney U Test of Hydrophobic Energies
 
The results of the Shapiro Wilk test show that both Type I and Type II protein 
groups violate the assumption of normality required by the Student’s T test. This is
indicated by the fact that the p values yielded by the Shapiro Wilk test using an Į = 0.05
for Type I and Type II protein groups are both significant (p = 0.000 and 0.017,
respectively). The results of the Levene’s test show that the data for Type I and Type II 
protein groups violate the assumption of homogeneity of variances required by the 
Student’s T test, given an alpha value of 0.05. This is indicated by the fact that the p
value yielded by the one-way ANOVA is less than 0.05. The Levene’s test yielded a p
value of 0.038. The descriptive statistics yielded a variance of 1749.9 and 2288.8 for 
Type I and Type II proteins, respectively. The results of the Mann-Whitney U test show 
that the mean ranks of Type I and Type II proteins are 650.24 and 541.51, respectively
(Table 1). The Mann-Whitney U Test that was performed in SPSS yielded a two-tailed 
asymptotic p value of 0.001 (Table 2), while the one-tailed test which was performed in 
Minitab yielded a significant p value of 0.0003 assuming a confidence level of 95%
(Table 3).
 
n (n +1) U =n n + 1   1 
 
- Sum of Ranks
1 1  2 2
 
U =n n - (U ) 
2 1  2 1
 
U =(1118)(155)+ 1118(1118+1)  -726967.50ĺ 71843.5
1 2
 
U =(1118)(155) -(71843.5) ĺ 101446.5
2
 
The value we compared to the U-critical value is the smaller of U
1
 
 
 
and U
2
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Table 1. Mean ranks of Type I and Type II TM protein hydrophobic energies
 
 
Table 2. Asymptotic two-tailed p value of Mann-Whitney U test of hydrophobic energies
 
Mann-Whitney Test and CI: T1 Hydro, T2 Hydro
 N Median
T1 Hydrophobicity 1118 55.650
T2 Hydrophobicity 155 53.200
Point estimate for Ș1 - Ș2 is 3.200
 
95.0 Percent CI for Ș1 - Ș2 is (1.400, 4.999) 
W = 726967.5
Test of Ș1 = Ș2 vs Ș1 < Ș2 is significant at 0.0003
 
The test is significant at 0.0003 (adjusted for ties)
 
 
 
Table 3. Left-tailed p value of the Mann-Whitney U test of hydrophobic energies
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U -
Z Test of Hydrophobic Energies
 
The results of the two independent sample Z test on the mean hydrophobic 
energies of Type I and Type II proteins yielded a standard deviation of 2389.2 and a Z-
test statistic of -3.4510, which corresponds to a p value of 0.0003, given n1=1118,
n2=155, aQGĮ = 0.05. This is in accordance with the results obtained by the Mann-
Whitney U test.
 
 
 
 
ξ(n n )(n +n +1)
Standard Deviation= 1 2     1    2 12
 
 
Standard Deviation=
ξ(1118*155)(1118+155+1)
12
 
Standard Deviation=4289.2
 
n n
12 2Z = 1
Standard Deviation
 
71843.5 - (1118)(155)
Z = 2 
4289.2
 
ĺ -3.4510
 
 
 
 
Frequency Distributions of Shannon Entropies
 
Histograms were constructed to provide preliminary and alternative visual 
assessment of the frequency distributions for both groups of proteins (Figures 4 and 5). 
Type I mean Shannon entropy was calculated to be 2.560 bits, while Type II mean
Shannon entropy was calculated to be 2.68 bits.
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Figure 4. Frequency distribution of Type I TM protein Shannon entropies
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Figure 5. Frequency distribution of Type II TM protein Shannon entropies
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Mann-Whitney U Test of Shannon Entropies
 
The results of the Shapiro Wilk test show that both Type I and Type II protein 
groups violate the assumption of normality required by the Student’s T test. This is
indicated by the fact that the p values yielded by the Shapiro Wilk test using Į = 0.05 for 
Type I and Type II protein groups are both significant (p = 0.000 and 0.000, respectively). 
The results of the Levene’s test show that the data for Type I and Type II protein groups 
violate the assumption of homogeneity of variances required by the Student’s T test,
given an alpha value of 0.05. This is indicated by the fact that the p value yielded by the
one way ANOVA is less than 0.05. The Levene’s test yielded a p-value of 0.000. The 
descriptive statistics yielded a variance of 0.078 and 0.196 for Type I and Type II 
proteins, respectively. The results of the Mann-Whitney U test show that the mean ranks 
of Type I and Type II Shannon entropies are 617.75 and 775.86 respectively (Table 4). 
The Mann-Whitney U test that was performed in SPSS yielded a two-tailed asymptotic p
value of 0.000 (Table 5), while the one-tailed test which was performed in Minitab 
yielded a p value of significant p value of 0.000 assuming a confidence level of 95%
(Table 6).
 
n (n +1) U =n n + 1   1 
 
- Sum of Ranks
1 1  2 2
 
U =n n - (U ) 
2 1  2 1
 
U =(1118)(155)+ 1118(1118+1)  - 690642.50ĺ 108168.5
1 2
 
U =(1118)(155) -(108168.5) ĺ 65121.5
2
 
The value we compared to the U-critical value is the smaller of U
1
 
 
 
and U
2
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Table 4. Mean ranks of Type I and Type II TM protein Shannon entropies
 
 
Table 5. Asymptotic two-tailed p value of Mann-Whitney U test of Shannon entropies
 
Mann-Whitney Test and CI: T1 SE, T2 Hydro
 N Median
T1 Shannon Entropies 1118 2.5708
T2 Shannon Entropies 155 2.7200
Point estimate for Ș1 - Ș2 is -0.1438
 
95.0 Percent CI for Ș1 - Ș2 is (-0.1970, -0.0889) 
W = 690642.5
Test of Ș1 = Ș2 vs Ș1 < Ș2 is significant at 0.0000
 
The test is significant at 0.0000 (adjusted for ties)
 
 
 
Table 6. Left-tailed p value of Mann-Whitney U test of Shannon entropies
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U -
Z Test of Shannon Entropies
 
The results of the two independent sample Z test on the mean Shannon entropies
of Type I and Type II proteins yielded a standard deviation of 4289.2 and a Z-test statistic 
of -5.018, which corresponds to a p value of 0.0000, given n1=1118, n2=155, aQGĮ =
0.05. This is in accordance with the results obtained by the Mann-Whitney U test.
 
 
 
 
ξ(n n )(n +n +1)
Standard Deviation= 1 2     1    2 12
 
 
Standard Deviation=
ξ(1118*155)(1118+155+1)
12
 
Standard Deviation=4289.2
 
n n
12 2Z = 2
Standard Deviation
 
65121.5 - (1118)(155)
Z = 2 
4289.2
 
ĺ -5.018
 
 
 
 
Shannon Entropy as a Function of Hydrophobic Energy
 
Shannon entropies of Type I proteins were plotted against hydrophobic energies 
of Type I proteins, and an R2 of 0.221 was obtained (Figure 6). The residual sum of 
squares was computed to be 67.7 (Table 7). Shannon entropies of Type II proteins were 
plotted against hydrophobic energies of Type II proteins, and R2 of 0.232 was obtained 
(Figure 7). The residual sum of squares was calculated to be 23.2 (Table 8).
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Figure 6. Linear regression plot of Type I Shannon entropies as a function of Type I TM
 
protein hydrophobic energies
 
 
 
Table 7. ANOVA table of linear regression analysis of Type I Shannon entropies plotted 
as a function of Type I hydrophobic energies
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Figure 7. Linear regression analysis of Type II Shannon entropies as a function of Type II 
TM protein hydrophobic energies
 
 
Table 8. ANOVA table of linear regression analysis of Type II Shannon entropies plotted 
as a function of Type II hydrophobic energies
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Functional Classification
 
The relative abundances of Type I (striped) and Type II (dotted) proteins 
categorized by biological, molecular, and enzymatic function. Among Type I proteins (n
= 1118), those that functioned in immune pathways were the most abundant, followed
closely by those that functioned exclusively as receptors (Figure 8). Similarly, among
Type II TM proteins (n = 155), those that functioned in immune pathways were the most 
abundant, followed by enzymes (Figure 8).
 
Figure 8. Classification of Protein Function
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Chapter V
 
DISCUSSION
 
Hydrophobic Energy Compensation
 
The overall Gibb’s free energy difference between Type I and Type II proteins 
was calculated to be approximately 9.63 kJ/mol. The mean hydrophobic energy yielded
by descriptive statistics was calculated to be 231.6 kJ/mol for Type I proteins and 217.1 
kJ/mol for Type II proteins. The difference in the mean hydrophobic energies between
the two types of proteins was calculated to be 14.5 kJ/mol. Thus, the difference in 
hydrophobic energies appears to exceed the free energy difference between Type I and
Type II proteins. Although hydrophobic energy appears to overcompensate for the 
energy disparity between Type I and Type II proteins, this observation may also be 
attributed to energy interactions among a variety of energetic contributors, but more 
research is needed in order to elucidate such factors and their specific roles in energy
compensation.
Z Test of Transmembrane Domain Hydrophobic Energies
 
The results of both the Z test and the Mann-Whitney U test of hydrophobic 
energies indicate that the mean hydrophobic energies of Type I proteins are significantly
greater than the mean hydrophobic energies of Type II proteins (p = 0.0003). The Z-test 
statistic for the hydrophobic energies was |-3.4510| > 1.96 IRUĮ = 0.05, indicating 
rejection of the null hypothesis. The mean rank of Type I protein hydrophobic energies
was calculated to be 650.24, while the mean rank of Type II protein hydrophobic energies
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was calculated to be 541.51. These results indicate significant disparities in the 
hydrophobic energies exhibited by Type I and Type II transmembrane domains.  Given
the estimated differences between the stabilities of Type I and Type II transmembrane 
proteins and the tendency of thermodynamic systems to achieve the lowest energy state 
possible, it may be hypothesized that such differences in hydrophobic energies may have 
arisen due to the energetic disadvantage of Type I protein orientation. The selective 
pressures exerted by energetically unfavorable interactions between the charged dipole
termini and the membrane field potential may impose evolutionary constraints on the 
hydrophobic character of transmembrane domains belonging to bitopic proteins, and 
perhaps those of polytopic proteins. It is possible that increased selection of
transmembrane proteins exhibiting greater hydrophobic character may serve as an
adaptive response to the subsequent energy disadvantages encountered by the globular
termini of Type I proteins. Admittedly, understanding of the mechanisms underlying this
process is still in its infancy, and more research is required to fully elucidate the 
evolutionary link between transmembrane protein selection and the hydropathies of their 
transmembrane domains.
Z Test of Transmembrane Domain Shannon Entropies
 
The results of both the Z test and the Mann-Whitney U test of Shannon entropies 
show that the mean information entropies of Type I transmembrane proteins are 
significantly lower than the Shannon entropies of Type II transmembrane proteins (p =
0.000). The Z-test statistic for Shannon entropies was |-5.018| > 1.96 for Į = 0.05,
indicating rejection of the null hypothesis. The mean rank of Type I transmembrane 
protein Shannon entropies was calculated to be 617.75, while the mean rank of Type II
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transmembrane protein Shannon entropies was calculated to be 775.86. These results
indicate that the maximum possible states that can be assumed by transmembrane 
domains of Type I proteins are much lower than the maximum possible states that can be 
assumed by Type II proteins. In addition, the amount of information that is needed to 
describe the state of Type I protein transmembrane domains is much lower than that 
needed to describe the state of Type II protein transmembrane domains. These disparities 
may be due to increased hydrophobicity in Type I protein transmembrane domains
relative to their Type II counterparts. This phenomenon may be attributed to the 
biochemical and stereochemical constraints that arise from Type I proteins’ evolutionary
need to assume a lower hydrophobic energy in order to compensate for free energy
disadvantages.  Specifically, the tendency of Type I proteins to exhibit greater
hydrophobicities in order to optimize energetic favorability may require the composition 
of their transmembrane domains to be dominated by hydrophobic residues or site-specific 
burial of hydrophilic side chains.
Linear Regression Analysis of Shannon Entropy as a Function of Hydrophobic Energy
 
The results of the linear regression analysis for Type I proteins reveal a weak
correlation between hydrophobic energy and Shannon entropy (R2 = 0.221, RSS = 67.7).
Similar results were obtained for Type II proteins (R2 = 0.232, RSS = 23.2). The weak
correlation between these two parameters indicates that the information entropies of 
transmembrane domains are not directly proportional to transmembrane domain 
hydrophobic energies. This means that transmembrane domain hydropathies are not the 
sole determinants of transmembrane domain entropies.  Given the results, it may be
hypothesized that overall entropies may actually be a product of multiple interactions
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among several energy inputs. Whether these interactions are additive or synergistic is 
unclear, and more research is needed in order to identify other forces that may influence
transmembrane domain entropies.
Functional Classification
 
It appears that differences in hydrophobic energy may not directly influence
protein functional roles. This is indicated by the fact that the majority of both Type I and
Type II protein groups were found to function in immune pathways.  For Type I proteins, 
the second most abundant functional role was found to receptors. For Type II proteins, 
the second most abundant functional role was enzymes. It is unclear whether these 
differences may be linked to disparities in hydrophobic energies of transmembrane 
domains.  More research is required to identify any specific correlations between
hydrophobic energy and protein function.
Summary
 
Thermodynamics is the guiding principal that governs all change. Examining the 
thermodynamic mechanisms underlying transmembrane protein stability is critical to
gaining a fundamental understanding of transmembrane protein energetics within lipid 
mediums and the evolutionary mechanisms that regulate their relative populations. This 
study exposes inherent differences between the hydrophobicities and the Shannon 
entropies exhibited by two broad categories of transmembrane proteins. The findings of
this study suggest that transmembrane protein insertion is not a strictly stochastic process
but ultimately one that is selectively governed by biophysical determinants. This study
also reveals that transmembrane domain entropies are not a direct result of hydrophobic
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free energies, but may be attributed to other energetic modulators, although these specific 
agents have yet to be identified.
Many diseases depend upon pathways involving transmembrane proteins and
their functional roles.  Certain diseases may interfere with transmembrane protein
function and disrupt normal pathways, or they may simply use transmembrane proteins to
elicit pathogenicity. Biomedical engineering of appropriate drugs depends very much on
a comprehensive understanding of transmembrane protein stability. By understanding the 
thermodynamic landscape of transmembrane protein stability, researchers can more 
effectively design disease-combatting drugs in order to improve the quality of human
health, and, in turn, the quality of human life.
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APPENDIX A: Kyte and Doolittle Amino Acid Hydrophobicity Indices
 
Ala: 1.800
 
Arg: -4.500
 
Asn: -3.500
 
Asp: -3.500
 
Cys: 2.500
 
Gln: -3.500
 
Glu: -3.500
 
Gly: -0.400
 
His: -3.200
 
Ile: 4.500
 
Leu: 3.800
 
Lys: -3.900
 
Met: 1.900
 
Phe: 2.800
 
Pro: -1.600
 
Ser: -0.800
 
Thr: -0.700
 
Trp: -0.900
 
Tyr: -1.300
 
Val: 4.200
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APPENDIX B: Type I Protein Hydrophobic Energies and Shannon Entropies
 
 
Uniprot
ID
 
Protein Name
Hydrophobic 
Energy
(kJ/mol)
Shannon
Entropy
(bits)
Q04771
P36896
Q8NER5
P27037
Q13705
Q15109
Q9UM73
Q7Z6M3
Q16586
Q86WK6
Q86SJ2
Q86WK7
P05067
P51693
Q06481
Q02763
P12821
Q9BYF1
Q9H6X2
P58335
A6NF34
P15813
Q16671
Q6UXC1
P16066
P20594
P17342
O75882
Q5VV63
Q7Z6A9
P50895
P35613
P11912
P40259
P20273
Q16620
P56817
Q9Y5Z0
Q9Y6X5
P15391
Q13145
Activin receptor type-1
Activin receptor type-1B 
Activin receptor type-1C 
Activin receptor type-2A 
Activin receptor type-2B
Advanced glycosylation end product-...
ALK tyrosine kinase receptor
Allergin-1
Alpha-sarcoglycan
Amphoterin-induced protein 1
Amphoterin-induced protein 2
Amphoterin-induced protein 3
Amyloid beta A4 protein
Amyloid-like protein 1
Amyloid-like protein 2
Angiopoietin-1 receptor 
Angiotensin-converting enzyme
Angiotensin-converting enzyme 2
Anthrax toxin receptor 1
Anthrax toxin receptor 2
Anthrax toxin receptor-like
Antigen-presenting glycoprotein CD1... 
Anti-Muellerian hormone type-2 rece... 
Apical endosomal glycoprotein
Atrial natriuretic peptide receptor...
Atrial natriuretic peptide receptor...
Atrial natriuretic peptide receptor...
Attractin
Attractin-like protein 1
B- and T-lymphocyte attenuator 
Basal cell adhesion molecule 
Basigin
B-cell antigen receptor complex-ass... 
B-cell antigen receptor complex-ass... 
B-cell receptor CD22
BDNF/NT-3 growth factors receptor
Beta-secretase 1
Beta-secretase 2
Bis(5'-adenosyl)-triphosphatase ENP...
B-lymphocyte antigen CD19
BMP and activin membrane-bound inhi...
285.35
314.22
212.97
200.83
184.93
192.88
206.27
275.31
242.25
194.14
199.16
196.65
265.68
196.65
288.28
212.55
178.24
278.65
261.50
260.66
183.26
242.25
274.47
221.33
216.73
168.20
189.95
211.29
211.29
188.70
247.27
217.99
208.36
253.13
206.27
280.33
221.33
251.04
250.62
203.34
251.46
2.559
2.255
3.082
3.252
2.834
2.451
2.895
2.211
2.009
2.856
2.710
2.492
2.674
2.610
2.717
2.895
2.686
2.250
1.787
2.559
2.375
2.623
1.765
2.331
2.558
2.722
2.799
2.371
2.371
2.262
2.246
2.833
2.894
2.376
2.676
2.661
2.841
2.686
2.815
3.033
2.570
53
 
 
P36894
O00238
Q13873
Q9BWV1
Q13410
Q7KYR7
Q8WVV5
O00481
P78410
O00478
A8MVZ5
Q6UXE8
Q6UX41
Q6UXG8
P12830
Q9Y6N8
P55287
P55289
P55291
O75309
Q12864
Q13634
Q9H159
P19022
Q9HBT6
Q9UJ99
Q9H251
Q86UP0
P22223
P55283
P33151
P55285
Q9ULB5
P55286
Q9ULB4
Q8IXH8
Q9BYE9
Q6ZTQ4
A6H8M9
Q9HBB8
Q9UQC9
O94985
Q9H4D0
Q9BQT9
O43570
Q9ULX7
Bone morphogenetic protein receptor...
Bone morphogenetic protein receptor...
Bone morphogenetic protein receptor...
Brother of CDO
Butyrophilin subfamily 1 member A1
Butyrophilin subfamily 2 member A1
Butyrophilin subfamily 2 member A2
Butyrophilin subfamily 3 member A1
Butyrophilin subfamily 3 member A2
Butyrophilin subfamily 3 member A3
Butyrophilin-like protein 10
Butyrophilin-like protein 3
Butyrophilin-like protein 8
Butyrophilin-like protein 9
Cadherin-1
Cadherin-10
Cadherin-11
Cadherin-12
Cadherin-15
Cadherin-16
Cadherin-17
Cadherin-18
Cadherin-19
Cadherin-2
Cadherin-20
Cadherin-22
Cadherin-23
Cadherin-24
Cadherin-3
Cadherin-4
Cadherin-5
Cadherin-6
Cadherin-7
Cadherin-8
Cadherin-9
Cadherin-like protein 26
Cadherin-related family member 2
Cadherin-related family member 3
Cadherin-related family member 4
Cadherin-related family member 5
Calcium-activated chloride channel ... 
Calsyntenin-1
Calsyntenin-2
Calsyntenin-3
Carbonic anhydrase 12
Carbonic anhydrase 14
243.51
257.32
253.13
247.27
241.84
244.76
246.02
124.26
176.56
157.32
211.29
238.07
196.65
214.64
283.26
321.75
317.57
334.72
284.93
217.15
261.50
329.70
270.70
313.80
298.32
311.29
257.73
266.94
310.03
289.11
270.70
297.48
283.68
302.92
314.64
232.21
260.24
247.69
197.48
235.14
230.96
264.43
259.41
271.54
261.08
228.03
2.965
2.641
2.627
2.644
3.065
2.790
2.757
2.484
2.567
2.669
2.936
2.669
2.514
2.324
1.655
2.119
2.495
2.764
1.843
2.589
2.474
2.655
2.421
2.345
2.269
2.159
2.338
2.453
1.917
2.653
2.407
2.305
2.416
2.347
2.054
2.213
2.628
2.316
2.365
1.822
2.820
2.628
2.739
2.567
2.584
2.667
54
 
 
Q16790
O75976
P13688
Q7Z692
Q6UY09
Q3KPI0
P40198
O75871
Q86XM0
Q6ZRH7
Q6UWJ8
Q13740
Q99467
Q15762
P26842
Q5ZPR3
Q8IX05
Q9NPF0
P16070
Q01151
P14209
Q8TCZ2
Q9BY67
Q8N3J6
Q8N126
Q8NFZ8
Q99795
Q8TD46
Q6Q8B3
P43121
Q6UVK1
O95196
Q9H9P2
Q8TDQ1
Q496F6
Q6UXZ3
Q08708
A8K4G0
Q9UGN4
Q6UXG3
Q9HBJ8
Q9NPY3
P17927
P20023
P78357
Q9UHC6
Carbonic anhydrase 9
Carboxypeptidase D
Carcinoembryonic antigen-related ce...
Carcinoembryonic antigen-related ce...
Carcinoembryonic antigen-related ce...
Carcinoembryonic antigen-related ce...
Carcinoembryonic antigen-related ce...
Carcinoembryonic antigen-related ce...
Cation channel sperm-associated pro...
Cation channel sperm-associated pro...
CD164 sialomucin-like 2 protein 
CD166 antigen
CD180 antigen
CD226 antigen
CD27 antigen
CD276 antigen
CD302 antigen
CD320 antigen
CD44 antigen
CD83 antigen
CD99 antigen
CD99 antigen-like protein 2
Cell adhesion molecule 1
Cell adhesion molecule 2
Cell adhesion molecule 3
Cell adhesion molecule 4
Cell surface A33 antigen
Cell surface glycoprotein CD200 rec... 
Cell surface glycoprotein CD200 rec... 
Cell surface glycoprotein MUC18
Chondroitin sulfate proteoglycan 4
Chondroitin sulfate proteoglycan 5
Chondrolectin
CMRF35-like molecule 1
CMRF35-like molecule 2
CMRF35-like molecule 4
CMRF35-like molecule 6
CMRF35-like molecule 7
CMRF35-like molecule 8
CMRF35-like molecule 9
Collectrin
Complement component C1q receptor
Complement receptor type 1
Complement receptor type 2
Contactin-associated protein 1
Contactin-associated protein-like 2
211.71
176.98
298.32
200.41
212.55
265.68
258.15
258.15
212.13
233.47
197.48
246.86
317.15
234.30
199.16
235.14
237.65
197.90
262.76
238.91
210.87
154.81
274.89
247.27
282.42
275.31
253.55
214.64
210.46
308.78
253.55
223.01
216.31
253.13
202.92
186.61
207.11
235.56
234.72
221.33
298.74
256.06
267.78
274.89
260.24
263.17
2.725
3.165
2.399
2.529
2.919
2.437
2.447
2.447
2.601
2.645
2.569
2.526
2.188
2.417
2.759
2.728
2.629
2.498
2.428
2.628
2.473
2.915
2.579
2.721
2.308
2.533
2.373
2.532
2.630
2.488
2.471
2.476
2.710
2.247
2.486
2.304
2.339
2.703
1.780
2.644
2.204
2.247
2.551
3.017
2.074
2.535
55
 
 
Q9BZ76
Q96NU0
Q9C0A0
Q8WYK1
P78310
Q86T13
Q9UBG0
Q96PZ7
Q86UP6
Q9H6B4
Q9H2A7
Q96J86
Q9NZV1
P32927
P31785
Q9HC73
O95727
P16410
Q8NFT8
O00548
Q9NYJ7
Q9NR61
Q08554
Q02487
Q14574
Q02413
Q14126
P32926
Q86SJ6
Q3MIW9
Q8N8Z6
Q96PD2
Q16832
O14672
O75078
O43184
Q13444
P78536
Q9Y3Q7
Q9H013
Q99965
O43506
Q9UKJ8
Q9P0K1
O75077
Q9UKQ2
Contactin-associated protein-like 3
Contactin-associated protein-like 3...
Contactin-associated protein-like 4
Contactin-associated protein-like 5
Coxsackievirus and adenovirus recep...
C-type lectin domain family 14 memb...
C-type mannose receptor 2
CUB and sushi domain-containing pro...
CUB and zona pellucida-like domain-...
CXADR-like membrane protein
C-X-C motif chemokine 16
Cysteine and tyrosine-rich protein ... 
Cysteine-rich motor neuron 1 protei... 
Cytokine receptor common subunit be... 
Cytokine receptor common subunit ga...
Cytokine receptor-like factor 2
Cytotoxic and regulatory T-cell mol...
Cytotoxic T-lymphocyte protein 4
Delta and Notch-like epidermal grow...
Delta-like protein 1
Delta-like protein 3
Delta-like protein 4
Desmocollin-1
Desmocollin-2
Desmocollin-3
Desmoglein-1
Desmoglein-2
Desmoglein-3
Desmoglein-4
Diffuse panbronchiolitis critical r...
Discoidin, CUB and LCCL domain-cont... 
Discoidin, CUB and LCCL domain-cont... 
Discoidin domain-containing recepto... 
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
272.38
261.50
269.45
272.80
242.25
252.71
283.26
203.76
178.24
227.19
230.96
239.32
270.70
235.98
197.90
227.19
266.52
169.87
291.21
287.44
190.79
240.58
251.88
252.30
241.42
220.50
288.70
258.57
244.76
321.33
234.72
264.85
315.89
182.84
194.14
227.19
186.61
192.88
215.06
249.78
240.16
234.30
194.97
243.51
192.46
255.64
2.512
2.710
2.579
2.226
2.162
2.380
2.049
2.569
2.785
2.602
2.828
2.147
2.416
2.168
2.936
2.280
2.109
2.633
2.437
2.523
2.170
2.265
2.961
2.528
2.555
2.535
2.233
1.839
2.262
2.016
2.552
2.432
2.311
2.856
2.584
2.769
2.522
2.671
2.421
2.487
2.454
2.113
2.571
2.320
2.584
2.512
56
 
 
Q9UKF5
Q9UKF2
Q8TC27
Q9BZ11
Q9H2U9
P78325
Q13443
O60469
Q8TD84
Q5VV43
Q14118
Q86XS8
Q68DV7
Q9ULT6
Q6PCB8
Q902F9
O71037
P61565
Q69384
Q902F8
Q9UKH3
Q9H9K5
B6SEH8
P17813
Q9ULC0
Q9HCU0
Q96AP7
Q19T08
Q9UNN8
P21709
Q5JZY3
P29317
P29320
P54764
P54756
Q9UF33
Q15375
P29322
P54762
P29323
P54753
P54760
O15197
P98172
P52799
Q15768
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Down syndrome cell adhesion molecul... 
Down syndrome cell adhesion molecul... 
Dyslexia-associated protein KIAA031...
Dystroglycan
E3 ubiquitin-protein ligase RNF130
E3 ubiquitin-protein ligase RNF43
E3 ubiquitin-protein ligase ZNRF3
Embigin
Endogenous retrovirus group K membe... 
Endogenous retrovirus group K membe...
Endogenous retrovirus group K membe... 
Endogenous retrovirus group K membe... 
Endogenous retrovirus group K membe... 
Endogenous retrovirus group K membe... 
Endogenous retrovirus group MER34 m... 
Endogenous retrovirus group V membe...
Endoglin
Endomucin
Endosialin
Endothelial cell-selective adhesion... 
Endothelial cell-specific chemotaxi... 
Endothelial protein C receptor
Ephrin type-A receptor 1
Ephrin type-A receptor 10
Ephrin type-A receptor 2
Ephrin type-A receptor 3
Ephrin type-A receptor 4
Ephrin type-A receptor 5
Ephrin type-A receptor 6
Ephrin type-A receptor 7
Ephrin type-A receptor 8
Ephrin type-B receptor 1
Ephrin type-B receptor 2
Ephrin type-B receptor 3
Ephrin type-B receptor 4
Ephrin type-B receptor 6
Ephrin-B1
Ephrin-B2
Ephrin-B3
239.32
256.06
222.17
179.08
306.27
297.48
278.65
284.51
221.75
172.38
251.46
234.30
208.78
255.64
218.82
230.12
230.12
230.12
230.12
230.12
230.12
232.21
141.42
223.84
267.78
261.50
212.13
300.83
236.40
261.50
222.17
236.81
290.79
275.73
266.10
216.73
257.32
264.85
240.16
245.60
245.18
277.40
235.14
264.01
268.19
155.64
2.226
2.283
2.710
2.471
2.070
2.144
2.335
2.269
2.780
2.707
3.090
2.603
2.991
2.553
2.805
2.567
2.567
2.567
2.567
2.567
2.567
2.630
2.579
2.679
2.574
2.477
2.136
1.969
2.435
2.230
2.659
2.208
2.761
2.340
2.452
2.463
2.458
2.452
2.620
2.474
2.401
2.167
2.512
2.421
2.608
1.873
57
 
 
P00533
Q6UW88
P16422
Q08345
Q8N766
Q5UCC4
Q9NPA0
Q96PL5
P19235
P16581
Q86XX4
Q96LA6
Q96LA5
Q96P31
Q96PJ5
Q96RD9
Q6DN72
P11362
P21802
P22607
P22455
Q8N441
P08F94
F2Z333
Q9H6D8
Q8NAU1
P49771
P78423
Q5SZK8
P09958
Q14802
P59646
Q96DB9
Q9H0Q3
P02724
P06028
P15421
Q9NU53
P55808
Q92896
I3L273
Q99062
P15509
P10912
P25092
Q9UBK5
Epidermal growth factor receptor
Epigen
Epithelial cell adhesion molecule
Epithelial discoidin domain-contain...
ER membrane protein complex subunit... 
ER membrane protein complex subunit... 
ER membrane protein complex subunit...
Erythroid membrane-associated prote... 
Erythropoietin receptor
E-selectin
Extracellular matrix protein FRAS1
Fc receptor-like protein 1
Fc receptor-like protein 2
Fc receptor-like protein 3
Fc receptor-like protein 4
Fc receptor-like protein 5
Fc receptor-like protein 6
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor 4
Fibroblast growth factor receptor-l... 
Fibrocystin
Fibronectin type III domain-contain... 
Fibronectin type III domain-contain... 
Fibronectin type III domain-contain... 
Fms-related tyrosine kinase 3 ligan...
Fractalkine
FRAS1-related extracellular matrix ...
Furin
FXYD domain-containing ion transpor...
FXYD domain-containing ion transpor...
FXYD domain-containing ion transpor...
FXYD domain-containing ion transpor...
Glycophorin-A
Glycophorin-B
Glycophorin-E
Glycoprotein integral membrane prot... 
Glycoprotein Xg
Golgi apparatus protein 1
Golgi-associated olfactory signalin...
Granulocyte colony-stimulating fact... 
Granulocyte-macrophage colony-stimu... 
Growth hormone receptor
Heat-stable enterotoxin receptor
Hematopoietic cell signal transduce...
242.25
194.56
330.12
305.43
122.59
135.98
195.39
292.88
296.65
179.08
253.97
129.70
177.82
211.29
192.05
160.67
198.74
187.02
252.30
217.15
191.63
207.53
182.84
235.98
233.05
227.19
222.59
193.30
198.32
259.41
209.20
179.08
186.61
219.66
220.50
279.91
206.69
193.30
182.42
195.39
227.61
227.19
235.14
248.11
293.72
204.18
2.596
2.738
1.930
2.200
3.142
3.183
2.327
2.487
2.141
2.476
2.630
3.181
2.378
2.432
2.250
2.720
2.754
3.086
2.895
2.838
2.488
2.919
2.620
2.951
2.864
2.875
2.022
2.599
2.756
2.603
2.892
2.584
2.684
2.700
2.803
2.698
2.895
2.852
2.864
2.764
2.569
2.417
2.814
2.606
2.481
2.479
58
 
 
P28906
Q96D42
Q8TDQ0
Q14CZ8
P08581
Q9BQS7
Q6MZM0
Q30201
Q8WWV6
P12319
P30273
P12314
Q92637
P04629
P30443
P13746
P01892
P30447
P05534
P18462
P30450
P30512
P04439
P16188
P16189
P10314
P16190
P30453
P30455
P30456
P30457
P01891
P10316
P30459
Q09160
P13747
P30511
P17693
P30461
P30462
P30464
P30466
P03989
P30685
P18463
Q95365
Hematopoietic progenitor cell antig...
Hepatitis A virus cellular receptor...
Hepatitis A virus cellular receptor...
Hepatocyte cell adhesion molecule 
Hepatocyte growth factor receptor
Hephaestin
Hephaestin-like protein 1
Hereditary hemochromatosis protein 
High affinity immunoglobulin alpha ... 
High affinity immunoglobulin epsilo...
High affinity immunoglobulin epsilo...
High affinity immunoglobulin gamma ...
High affinity immunoglobulin gamma ...
High affinity nerve growth factor r...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
182.84
246.02
205.43
197.48
220.08
238.91
264.85
284.09
174.05
201.25
189.95
196.65
196.65
189.12
241.84
241.84
237.65
241.84
241.84
248.11
248.11
214.22
241.84
241.84
214.22
204.60
214.22
245.18
241.84
248.11
248.11
237.65
227.19
204.60
252.30
240.16
241.00
238.49
249.78
249.78
239.32
239.32
286.19
275.73
275.73
286.19
2.769
2.756
2.379
2.919
2.624
2.527
2.360
2.395
2.667
2.575
2.762
2.947
2.947
2.135
2.725
2.725
2.707
2.725
2.725
2.544
2.544
2.500
2.725
2.725
2.500
2.663
2.500
2.544
2.725
2.544
2.544
2.707
2.455
2.663
2.563
2.620
2.496
2.551
2.574
2.574
2.736
2.736
2.385
2.548
2.548
2.385
59
 
 
P30475
Q04826
P30479
P30480
P30481
P30483
P30484
P30485
P30486
P30487
P30488
P18464
P30490
P30491
P30492
P30493
P30495
P18465
P10319
Q29940
Q29836
P01889
Q31612
P30498
P30460
Q31610
Q29718
P30499
P30508
P30510
Q07000
Q29960
Q95604
Q29865
P30501
P04222
P30504
Q9TNN7
Q29963
P10321
P30505
P06340
P13765
P20036
P04440
P01909
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti...
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti... 
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class I histocompatibility anti...
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant...
286.19
286.19
249.78
249.78
249.78
239.32
239.32
259.41
249.78
239.32
239.32
275.73
275.73
275.73
275.73
275.73
275.73
286.19
275.73
275.73
286.19
249.78
301.25
275.73
249.78
286.19
275.73
299.16
289.53
299.16
289.53
299.16
272.38
309.20
299.16
299.16
289.53
289.53
289.53
269.45
289.53
246.86
243.93
264.01
172.80
241.00
2.385
2.385
2.574
2.574
2.574
2.736
2.736
2.385
2.574
2.736
2.736
2.548
2.548
2.548
2.548
2.548
2.548
2.385
2.548
2.548
2.385
2.574
2.341
2.548
2.574
2.385
2.548
2.372
2.473
2.372
2.473
2.372
1.968
2.341
2.372
2.372
2.473
2.473
2.473
2.693
2.473
2.635
2.535
2.562
2.689
2.683
60
 
 
P01906
P01920
P05538
P01903
P79483
P13762
Q30154
P04229
Q30167
P20039
P01911
P01912
P13760
P13761
Q30134
Q9TQE0
O75144
Q9H665
P55899
A6NFU0
P24071
Q8IVU1
Q8TDY8
Q5DX21
Q93033
O75054
Q9NSI5
O95976
Q86SU0
Q13308
Q01973
Q9Y6W8
Q6GPH6
Q3MIP1
P06213
P14616
P08069
P98153
P56199
O75578
Q9UKX5
P17301
P26006
P13612
P08648
P23229
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant...
HLA class II histocompatibility ant...
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant…
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant...
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
HLA class II histocompatibility ant... 
ICOS ligand
IGF-like family receptor 1
IgG receptor FcRn large subunit p51
Ig-like V-type domain-containing pr...
Immunoglobulin alpha Fc receptor 
Immunoglobulin superfamily DCC subc...
Immunoglobulin superfamily DCC subc...
Immunoglobulin superfamily member 1...
Immunoglobulin superfamily member 2
Immunoglobulin superfamily member 3
Immunoglobulin superfamily member 5
Immunoglobulin superfamily member 6
Immunoglobulin-like domain-containi... 
Inactive tyrosine-protein kinase 7
Inactive tyrosine-protein kinase tr...
Inducible T-cell costimulator 
Inositol 1,4,5-trisphosphate recept... 
Inositol 1,4,5-trisphosphate recept... 
Insulin receptor
Insulin receptor-related protein Insulin-
like growth factor 1 recept... Integral
membrane protein DGCR2/IDD Integrin 
alpha-1
Integrin alpha-10
Integrin alpha-11
Integrin alpha-2
Integrin alpha-3
Integrin alpha-4
Integrin alpha-5
Integrin alpha-6
229.70
206.27
206.27
233.47
192.88
192.88
186.61
192.88
192.88
192.88
186.61
192.88
192.88
192.88
192.88
192.88
237.65
309.62
255.22
167.36
220.92
249.78
226.35
241.42
260.24
200.83
115.48
199.58
257.32
187.44
243.09
231.79
115.06
166.94
253.97
210.04
264.43
214.22
259.83
245.60
230.96
253.97
267.78
225.52
282.42
279.07
2.892
2.213
2.213
2.722
2.433
2.433
2.313
2.433
2.433
2.433
2.313
2.433
2.433
2.433
2.433
2.433
2.761
1.962
2.542
2.916
2.484
2.504
2.606
2.477
1.978
2.323
2.776
2.852
2.532
2.864
2.576
2.821
2.730
2.627
2.466
2.516
2.821
2.311
2.351
2.474
2.609
2.526
2.195
2.751
2.440
2.746
61
 
 
Q13683
P53708
Q13797
Q13349
P38570
P08514
P20701
P11215
P06756
P20702
P05556
P05107
P05106
P16144
P18084
P18564
P26010
P26012
P05362
P13598
P32942
Q14773
Q9UMF0
P17181
P48551
P15260
P38484
Q8IU57
Q9NPH3
Q9NZN1
P14778
P27930
Q01638
Q9HB29
Q13651
Q08334
Q14626
P42701
Q99665
P78552
Q14627
Q13261
Q96F46
Q9NRM6
Q8NAC3
Q8NFM7
Integrin alpha-7
Integrin alpha-8
Integrin alpha-9
Integrin alpha-D
Integrin alpha-E
Integrin alpha-IIb
Integrin alpha-L
Integrin alpha-M
Integrin alpha-V
Integrin alpha-X
Integrin beta-1
Integrin beta-2
Integrin beta-3
Integrin beta-4
Integrin beta-5
Integrin beta-6
Integrin beta-7
Integrin beta-8
Intercellular adhesion molecule 1
Intercellular adhesion molecule 2
Intercellular adhesion molecule 3
Intercellular adhesion molecule 4
Intercellular adhesion molecule 5
Interferon alpha/beta receptor 1
Interferon alpha/beta receptor 2
Interferon gamma receptor 1
Interferon gamma receptor 2
Interferon lambda receptor 1
Interleukin-1 receptor accessory pr...
Interleukin-1 receptor accessory pr...
Interleukin-1 receptor type 1
Interleukin-1 receptor type 2
Interleukin-1 receptor-like 1
Interleukin-1 receptor-like 2
Interleukin-10 receptor subunit alp... 
Interleukin-10 receptor subunit bet... 
Interleukin-11 receptor subunit alp... 
Interleukin-12 receptor subunit bet... 
Interleukin-12 receptor subunit bet... 
Interleukin-13 receptor subunit alp... 
Interleukin-13 receptor subunit alp... 
Interleukin-15 receptor subunit alp... 
Interleukin-17 receptor A
Interleukin-17 receptor B 
Interleukin-17 receptor C 
Interleukin-17 receptor D
281.16
267.78
274.47
190.79
258.99
251.04
227.19
189.12
279.07
197.90
269.87
256.06
275.31
246.44
245.18
245.18
190.79
256.48
189.12
296.65
277.40
169.87
145.18
223.43
211.29
240.58
198.32
230.12
217.15
199.16
191.21
170.71
255.64
199.16
233.47
234.72
180.75
216.73
179.91
276.56
217.15
184.10
217.57
200.83
228.45
200.00
1.973
2.331
2.360
2.887
2.483
2.844
2.244
2.855
2.705
2.718
2.583
2.599
2.632
1.775
2.821
2.821
2.873
2.115
3.012
2.486
2.613
2.774
2.035
2.816
2.610
2.469
2.766
2.667
2.567
2.813
2.990
3.074
2.805
2.684
2.576
2.898
2.401
2.567
3.006
2.782
2.384
2.914
2.741
2.833
2.240
2.721
62
 
 
Q8NFR9
Q13478
O95256
P01589
P14784
Q9UHF4
Q6UXL0
Q9HBE5
Q8N6P7
Q5VWK5
Q6UWB1
P26951
Q8NI17
P24394
Q01344
P08887
P40189
P16871
Q01113
Q9BZV3
Q8IYV9
Q6UXV1
Q5VZ72
Q9Y624
P57087
Q9BX67
Q86YT9
Q8NC54
P43626
P43627
P43628
Q99706
Q8N109
Q8NHK3
Q14954
P43631
Q14952
P43632
Q14953
P43629
P43630
Q8N743
Q14943
Q96J84
Q6UWL6
Q8IZU9
Interleukin-17 receptor E 
Interleukin-18 receptor 1
Interleukin-18 receptor accessory p...
Interleukin-2 receptor subunit alph... 
Interleukin-2 receptor subunit beta 
Interleukin-20 receptor subunit alp... 
Interleukin-20 receptor subunit bet... 
Interleukin-21 receptor
Interleukin-22 receptor subunit alp... 
Interleukin-23 receptor
Interleukin-27 receptor subunit alp... 
Interleukin-3 receptor subunit alph... 
Interleukin-31 receptor subunit alp...
Interleukin-4 receptor subunit alph... 
Interleukin-5 receptor subunit alph... 
Interleukin-6 receptor subunit alph... 
Interleukin-6 receptor subunit beta 
Interleukin-7 receptor subunit alph... 
Interleukin-9 receptor 
Interphotoreceptor matrix proteogly...
Izumo sperm-egg fusion protein 1
Izumo sperm-egg fusion protein 2
Izumo sperm-egg fusion protein 3
Junctional adhesion molecule A
Junctional adhesion molecule B 
Junctional adhesion molecule C 
Junctional adhesion molecule-like 
Keratinocyte-associated transmembra...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Kin of IRRE-like protein 1
Kin of IRRE-like protein 2
Kin of IRRE-like protein 3
261.08
285.35
209.62
211.71
213.38
169.03
265.27
164.43
154.81
242.67
184.51
222.59
238.07
258.57
265.27
194.56
241.42
264.85
138.07
247.69
202.51
273.22
248.53
253.55
246.44
228.86
287.02
166.52
251.88
251.88
266.52
173.64
243.09
243.09
174.05
189.95
171.13
189.95
171.13
267.78
259.41
222.17
191.21
228.03
186.19
235.56
1.927
2.659
2.629
2.539
2.854
2.992
2.306
2.755
2.705
2.571
2.547
2.758
2.396
2.861
2.614
2.780
2.628
2.794
2.916
2.548
2.492
2.338
2.433
2.566
2.587
2.429
2.548
2.733
2.171
2.171
2.177
2.933
2.401
2.401
2.677
2.641
2.632
2.641
2.632
2.134
2.139
2.725
2.617
2.411
2.661
2.579
63
 
 
P21583
Q9UEF7
Q96MU8
Q8NCW0
O43291
P09848
Q6UX15
P48357
Q9P244
Q9ULH4
Q9BTN0
Q6PJG9
Q96NI6
Q96FE5
Q7L985
P0C6S8
Q6UY18
Q9HBL6
Q8N967
Q6UXK5
O75325
Q9H3W5
Q8WUT4
Q86UE6
O43300
Q86VH5
Q86VH4
Q8TF66
Q9H756
Q8N386
Q2I0M4
Q14392
A6NMS7
A6NM11
O60309
Q96QE4
Q9HBW1
Q96JA1
O94898
P42702
O75019
Q8N149
P59901
A6NI73
Q6PI73
Q8NHL6
Kit ligand
Klotho
Kremen protein 1
Kremen protein 2
Kunitz-type protease inhibitor 2
Lactase-phlorizin hydrolase
Layilin
Leptin receptor
Leucine-rich repeat and fibronectin...
Leucine-rich repeat and fibronectin...
Leucine-rich repeat and fibronectin...
Leucine-rich repeat and fibronectin...
Leucine-rich repeat and fibronectin... 
Leucine-rich repeat and immunoglobu... 
Leucine-rich repeat and immunoglobu... 
Leucine-rich repeat and immunoglobu... 
Leucine-rich repeat and immunoglobu... 
Leucine-rich repeat and transmembra...
Leucine-rich repeat and transmembra...
Leucine-rich repeat neuronal protei... 
Leucine-rich repeat neuronal protei... 
Leucine-rich repeat neuronal protei...
Leucine-rich repeat neuronal protei... 
Leucine-rich repeat transmembrane n...
Leucine-rich repeat transmembrane n...
Leucine-rich repeat transmembrane n...
Leucine-rich repeat transmembrane n...
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeats and immunoglob... 
Leucine-rich repeats and immunoglob... 
Leukemia inhibitory factor receptor 
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
163.18
220.50
194.97
208.36
251.46
200.83
223.84
221.33
276.56
285.35
266.52
235.14
293.30
218.82
217.15
225.94
192.88
225.10
237.65
182.00
218.40
225.10
182.42
229.28
235.98
255.64
237.65
244.35
232.63
203.76
157.74
239.74
284.51
284.51
287.02
303.34
237.65
223.84
278.65
300.41
200.83
199.58
192.05
135.56
184.10
320.49
2.766
2.108
2.748
2.647
2.494
2.409
2.684
2.844
2.538
2.479
2.566
2.186
2.247
2.633
2.525
2.740
2.916
3.023
2.563
2.780
2.123
2.665
2.512
2.761
2.454
2.569
2.782
2.527
2.589
2.756
2.859
2.502
2.381
2.381
2.218
2.237
2.857
2.724
2.416
2.777
2.733
2.710
2.623
3.222
2.725
1.827
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Q8N423
O75022
Q8NHJ6
O75023
P29376
Q6GTX8
P16150
Q86UK5
P12318
P31994
P31995
P08637
P01130
Q5SZI1
Q86YD5
Q7Z4F1
Q86VZ4
Q9Y561
Q9NZR2
P98164
O75074
O75096
O75197
O75581
Q14114
Q8ND94
P14151
Q9Y5Y7
P18627
Q5SQ64
O60449
P19256
Q9UJQ1
P07333
P22897
Q2M385
Q04912
P34810
Q95460
Q9H8J5
A6NHS7
P10721
P50281
P51511
P51512
Q9Y5R2
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte immunoglobulin-like recep...
Leukocyte tyrosine kinase receptor 
Leukocyte-associated immunoglobulin... 
Leukosialin
Limbin
Low affinity immunoglobulin gamma F...
Low affinity immunoglobulin gamma F...
Low affinity immunoglobulin gamma F...
Low affinity immunoglobulin gamma F...
Low-density lipoprotein receptor
Low-density lipoprotein receptor cl... 
Low-density lipoprotein receptor cl... 
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
Low-density lipoprotein receptor-re...
LRRN4 C-terminal-like protein
L-selectin
Lymphatic vessel endothelial hyalur...
Lymphocyte activation gene 3 protei... 
Lymphocyte antigen 6 complex locus ... 
Lymphocyte antigen 75
Lymphocyte function-associated anti...
Lysosome-associated membrane glycop...
Macrophage colony-stimulating facto... 
Macrophage mannose receptor 1
Macrophage-expressed gene 1 protein 
Macrophage-stimulating protein rece...
Macrosialin
Major histocompatibility complex cl... 
MANSC domain-containing protein 1
MANSC domain-containing protein 4
Mast/stem cell growth factor recept... 
Matrix metalloproteinase-14
Matrix metalloproteinase-15
Matrix metalloproteinase-16
Matrix metalloproteinase-24
319.24
285.77
286.19
265.68
280.33
286.19
297.06
215.06
284.93
193.30
275.73
181.17
261.08
63.18
244.35
228.03
223.01
229.28
275.31
279.91
226.35
240.16
201.25
160.67
238.07
182.42
205.02
203.34
228.45
219.66
241.00
179.91
215.89
263.17
224.26
198.74
243.51
335.56
191.63
246.86
225.94
236.40
274.47
240.16
257.73
248.53
1.827
1.923
1.863
1.974
2.752
2.171
2.261
2.633
2.121
2.703
2.310
2.857
2.603
2.822
2.592
2.779
2.691
2.779
2.610
2.430
2.748
2.659
3.005
2.559
2.951
2.625
2.994
2.273
2.205
2.813
3.001
3.236
2.790
2.394
2.630
2.489
2.188
2.239
2.718
2.221
2.936
2.919
1.909
2.481
2.741
2.836
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Q9BRK3
P15529
Q8TBP5
Q3ZCQ3
Q16819
Q16820
Q96KJ4
Q86V40
A6NFA1
Q29983
Q29980
P55082
O75121
P15941
Q9UKN1
Q9H3R2
Q8N387
Q8WXI7
Q5SSG8
Q13477
Q96KG7
A6BM72
Q7Z7M0
Q9H1U4
O15146
P25189
O95297
O60487
Q6UWV2
P20916
P20138
O76036
O95944
O14931
Q68D85
Q9BZW8
Q15223
Q92692
Q96NY8
Q86YC3
Q92859
O60500
P43146
Q6ZN44
Q8IZJ1
O95185
Matrix-remodeling-associated protei... 
Membrane cofactor protein
Membrane protein FAM174A 
Membrane protein FAM174B 
Meprin A subunit alpha 
Meprin A subunit beta 
Mesothelin-like protein 
Metalloprotease TIKI1
Metalloprotease TIKI2
MHC class I polypeptide-related seq...
MHC class I polypeptide-related seq...
Microfibril-associated glycoprotein... 
Microfibrillar-associated protein 3... 
Mucin-1
Mucin-12
Mucin-13
Mucin-15
Mucin-16
Mucin-21
Mucosal addressin cell adhesion mol... 
Multiple epidermal growth factor-li...
Multiple epidermal growth factor-li...
Multiple epidermal growth factor-li...
Multiple epidermal growth factor-li...
Muscle, skeletal receptor tyrosine-...
Myelin protein P0
Myelin protein zero-like protein 1
Myelin protein zero-like protein 2
Myelin protein zero-like protein 3
Myelin-associated glycoprotein
Myeloid cell surface antigen CD33
Natural cytotoxicity triggering rec...
Natural cytotoxicity triggering rec...
Natural cytotoxicity triggering rec...
Natural cytotoxicity triggering rec...
Natural killer cell receptor 2B4
Nectin-1
Nectin-2
Nectin-4
Negative regulator of reactive oxyg...
Neogenin
Nephrin
Netrin receptor DCC
Netrin receptor UNC5A 
Netrin receptor UNC5B
Netrin receptor UNC5C
244.35
285.35
187.86
217.57
209.62
240.58
203.34
163.18
162.76
178.66
192.88
172.80
184.51
285.35
281.16
243.93
200.83
225.94
231.38
143.51
305.43
250.20
236.81
287.02
191.63
286.60
223.84
267.36
258.15
186.19
235.98
170.29
205.02
150.21
181.17
251.88
243.09
218.40
309.62
226.35
298.32
146.44
342.67
288.70
274.05
287.44
2.247
2.368
2.686
2.494
3.047
2.669
3.280
2.761
2.995
2.571
2.916
3.190
3.157
2.610
2.407
2.642
2.592
2.800
2.514
2.583
2.141
2.433
1.778
2.447
2.744
2.204
2.644
2.705
2.250
2.871
2.641
2.761
2.567
2.738
2.800
2.689
2.322
2.189
2.016
2.790
2.149
2.185
2.277
2.320
2.221
2.401
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Q6UXZ4
P13591
O15394
P32004
O00533
Q9ULB1
P58400
Q9P2S2
P58401
Q9Y4C0
Q9HDB5
O94856
P46531
Q04721
Q9UM47
Q99466
Q8N2Q7
Q8NFZ4
Q9NZ94
Q8N0W4
Q8NFZ3
Q92823
Q8TDF5
Q8NC67
O14786
O60462
Q9Y639
Q8NET5
Q92542
Q8TD07
Q15155
P69849
Q5T1S8
Q16288
Q99650
Q96PE5
P41217
Q9UKJ1
Q9UKJ0
Q9UMZ3
Q96FE7
O00168
Q6P1J6
Q8IYJ0
P53801
P16284
Netrin receptor UNC5D
Neural cell adhesion molecule 1
Neural cell adhesion molecule 2
Neural cell adhesion molecule L1
Neural cell adhesion molecule L1-li...
Neurexin-1
Neurexin-1-beta
Neurexin-2
Neurexin-2-beta
Neurexin-3
Neurexin-3-beta
Neurofascin
Neurogenic locus notch homolog prot... 
Neurogenic locus notch homolog prot... 
Neurogenic locus notch homolog prot... 
Neurogenic locus notch homolog prot... 
Neuroligin-1
Neuroligin-2
Neuroligin-3
Neuroligin-4, X-linked
Neuroligin-4, Y-linked
Neuronal cell adhesion molecule 
Neuropilin and tolloid-like protein... 
Neuropilin and tolloid-like protein... 
Neuropilin-1
Neuropilin-2
Neuroplastin
NFAT activation molecule 1
Nicastrin
NKG2D ligand 4
Nodal modulator 1
Nodal modulator 3
Noncompact myelin-associated protei... 
NT-3 growth factor receptor
Oncostatin-M-specific receptor subu... 
Opalin
OX-2 membrane glycoprotein
Paired immunoglobulin-like type 2 r...
Paired immunoglobulin-like type 2 r...
Phosphatidylinositol phosphatase PT...
Phosphoinositide-3-kinase-interacti...
Phospholemman
Phospholipase B1, membrane-associat... 
PILR alpha-associated neural protei... 
Pituitary tumor-transforming gene 1...
Platelet endothelial cell adhesion ...
214.64
269.87
233.47
283.26
243.93
228.03
210.87
228.03
228.03
228.03
228.03
290.37
220.50
295.39
264.43
213.38
185.35
184.10
184.10
185.35
185.35
284.93
257.73
230.54
254.81
222.17
233.89
193.30
205.85
230.54
116.73
116.73
313.80
283.68
235.56
217.57
261.92
249.37
244.35
233.05
214.64
241.42
175.31
201.67
203.76
258.99
2.553
2.479
2.201
2.516
2.659
2.815
3.084
2.815
2.815
2.815
2.815
2.494
2.455
2.281
2.320
2.659
2.775
2.739
2.739
2.775
2.775
2.696
2.386
2.432
2.910
2.997
2.746
2.285
2.721
2.876
3.142
3.142
2.098
2.645
2.733
2.360
2.538
2.739
2.426
2.669
2.695
2.293
2.659
2.762
3.023
2.187
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P07359
P13224
P14770
P40197
P16234
P09619
Q8IUK5
Q6UX71
Q9UIW2
O75051
P51805
Q9HCM2
O43157
O15031
Q9ULL4
O60486
O00592
Q9NZ53
Q86YL7
P15151
P01833
Q8N131
Q6ISU1
P35070
P01133
O14944
Q9NZQ7
Q9BQ51
Q15116
Q99075
P16471
Q86XR5
Q07954
Q02297
O14511
P56975
Q8WWG1
Q92824
Q16549
Q9P2B2
Q6UWI2
Q9BXJ7
Q8J025
Q4G0I0
P82279
Q9BUF7
Platelet glycoprotein Ib alpha chai... 
Platelet glycoprotein Ib beta chain
Platelet glycoprotein IX
Platelet glycoprotein V
Platelet-derived growth factor rece...
Platelet-derived growth factor rece...
Plexin domain-containing protein 1
Plexin domain-containing protein 2
Plexin-A1
Plexin-A2
Plexin-A3
Plexin-A4
Plexin-B1
Plexin-B2
Plexin-B3
Plexin-C1
Podocalyxin
Podocalyxin-like protein 2
Podoplanin
Poliovirus receptor
Polymeric immunoglobulin receptor
Porimin
Pre T-cell antigen receptor alpha
Probetacellulin
Pro-epidermal growth factor
Proepiregulin
Programmed cell death 1 ligand 1
Programmed cell death 1 ligand 2
Programmed cell death protein 1
Proheparin-binding EGF-like growth ... 
Prolactin receptor
Proline-rich membrane anchor 1
Prolow-density lipoprotein receptor...
Pro-neuregulin-1, membrane-bound is... 
Pro-neuregulin-2, membrane-bound is... 
Pro-neuregulin-3, membrane-bound is... 
Pro-neuregulin-4, membrane-bound is... 
Proprotein convertase subtilisin/ke...
Proprotein convertase subtilisin/ke...
Prostaglandin F2 receptor negative ...
Prostate androgen-regulated mucin-l... 
Protein amnionless
Protein APCDD1
Protein CCSMST1
Protein crumbs homolog 1
Protein crumbs homolog 3
225.52
225.10
205.02
226.35
304.60
287.02
268.19
268.61
230.12
260.66
193.30
266.10
203.34
233.05
191.21
246.44
220.92
296.65
270.29
266.52
222.17
171.54
184.10
312.54
271.96
197.90
213.38
226.77
230.96
289.95
248.95
287.02
262.34
250.62
253.97
231.79
205.02
203.76
151.04
186.19
230.12
229.28
132.21
173.22
251.04
271.96
2.421
2.065
2.242
2.730
2.256
2.332
2.416
2.434
2.244
2.432
2.529
2.424
2.851
2.659
2.739
2.630
3.050
2.383
2.198
2.467
2.453
2.764
2.023
2.447
2.511
2.761
2.725
2.567
2.337
2.736
2.824
2.569
2.783
2.997
2.623
2.725
2.802
2.895
2.816
2.761
2.538
1.913
3.002
2.884
2.553
2.246
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P80370
Q6UY11
P0C7U0
P58658
P22794
P34910
Q5VUB5
A8MVW0
Q6P995
Q17R55
Q5JX71
Q5JX69
O95866
Q9ULI3
A8MVS5
P78504
Q9Y219
O76095
Q8TBQ9
Q9NRX6
Q5SGD2
Q5TEA6
Q6UWI4
Q96DD7
Q8N114
Q6ZSJ9
B4DS77
Q7Z5N4
Q58EX2
Q9P2J2
Q9UPX0
Q9Y5I3
Q9Y5I2
Q9Y5I1
Q9UN75
Q9Y5I0
Q9Y5H9
Q9Y5H8
Q9UN74
Q9Y5H7
Q9UN73
Q9UN72
Q9Y5H6
Q9Y5H5
Q9H158
Q9Y5I4
Protein delta homolog 1
Protein delta homolog 2
Protein ELFN1
Protein eva-1 homolog C
Protein EVI2A
Protein EVI2B 
Protein FAM171A1
Protein FAM171A2
Protein FAM171B 
Protein FAM187B 
Protein FAM209A 
Protein FAM209B 
Protein G6b
Protein HEG homolog 1
Protein HIDE1
Protein jagged-1
Protein jagged-2
Protein JTB 
Protein kish-A
Protein kish-B
Protein phosphatase 1L
Protein sel-1 homolog 2
Protein shisa-2 homolog
Protein shisa-4
Protein shisa-5
Protein shisa-6 homolog
Protein shisa-9
Protein sidekick-1
Protein sidekick-2
Protein turtle homolog A
Protein turtle homolog B
Protocadherin alpha-1
Protocadherin alpha-10
Protocadherin alpha-11
Protocadherin alpha-12
Protocadherin alpha-13
Protocadherin alpha-2
Protocadherin alpha-3
Protocadherin alpha-4
Protocadherin alpha-5
Protocadherin alpha-6
Protocadherin alpha-7
Protocadherin alpha-8
Protocadherin alpha-9
Protocadherin alpha-C1
Protocadherin alpha-C2
248.11
241.00
191.21
229.70
283.26
266.52
269.45
290.79
232.63
200.83
136.40
126.36
193.30
229.28
230.54
222.17
213.80
200.83
173.64
178.66
119.24
167.36
221.33
222.17
216.31
183.26
223.84
276.56
322.59
232.63
215.89
225.52
225.52
235.56
225.52
225.52
227.19
224.26
225.52
225.52
225.52
225.52
225.52
225.52
256.48
246.86
2.731
2.109
3.031
2.769
2.404
2.886
2.332
1.981
2.480
2.773
2.816
2.970
2.290
2.429
2.305
3.030
2.669
2.861
2.951
2.947
2.699
2.710
2.666
2.797
2.666
2.689
2.936
2.297
2.030
2.453
2.721
2.718
2.718
2.659
2.718
2.718
2.761
2.695
2.718
2.718
2.718
2.718
2.718
2.718
2.442
2.226
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Q9Y5F3
Q9UN67
Q9Y5F2
Q9Y5F1
Q9Y5F0
Q9Y5E9
Q9Y5E8
Q9NRJ7
Q9Y5E7
Q9Y5E6
Q9Y5E5
Q9Y5E4
Q9Y5E3
Q9Y5E2
Q9UN66
Q9Y5E1
Q14517
Q9NYQ8
Q8TDW7
Q6V0I7
Q9Y5H4
Q9Y5H3
Q9Y5H2
O60330
Q9Y5H1
Q9Y5H0
Q9Y5G9
Q9Y5G8
Q9Y5G7
Q9Y5G6
Q9Y5G5
Q9Y5G4
Q9Y5G3
Q9Y5G2
Q9Y5G1
Q9UN71
Q9Y5G0
Q9Y5F9
Q9Y5F8
Q9UN70
Q9Y5F7
Q9Y5F6
Q08174
Q9P2E7
Q9BZA7
Q9BZA8
Protocadherin beta-1
Protocadherin beta-10
Protocadherin beta-11
Protocadherin beta-12
Protocadherin beta-13
Protocadherin beta-14
Protocadherin beta-15
Protocadherin beta-16
Protocadherin beta-2
Protocadherin beta-3
Protocadherin beta-4
Protocadherin beta-5
Protocadherin beta-6
Protocadherin beta-7
Protocadherin beta-8
Protocadherin beta-9
Protocadherin Fat 1
Protocadherin Fat 2
Protocadherin Fat 3
Protocadherin Fat 4
Protocadherin gamma-A1
Protocadherin gamma-A10
Protocadherin gamma-A11
Protocadherin gamma-A12
Protocadherin gamma-A2
Protocadherin gamma-A3
Protocadherin gamma-A4
Protocadherin gamma-A5
Protocadherin gamma-A6
Protocadherin gamma-A7
Protocadherin gamma-A8
Protocadherin gamma-A9
Protocadherin gamma-B1
Protocadherin gamma-B2
Protocadherin gamma-B3
Protocadherin gamma-B4
Protocadherin gamma-B5
Protocadherin gamma-B6
Protocadherin gamma-B7
Protocadherin gamma-C3
Protocadherin gamma-C4
Protocadherin gamma-C5
Protocadherin-1
Protocadherin-10
Protocadherin-11 X-linked
Protocadherin-11 Y-linked
287.86
233.47
229.28
229.28
229.28
254.39
225.10
229.28
229.28
229.28
229.28
229.28
229.28
233.47
204.18
233.47
275.31
232.63
315.89
218.40
263.59
273.63
284.93
271.96
273.63
273.63
251.88
251.88
273.63
260.24
254.39
252.71
284.09
269.03
273.22
276.14
282.84
284.09
284.09
251.88
205.85
194.14
268.61
262.76
245.60
245.60
1.987
1.987
1.987
1.987
1.987
2.280
1.966
1.987
1.987
1.987
1.987
1.987
1.987
1.987
1.955
1.987
2.271
2.721
2.021
2.856
2.213
2.202
2.278
2.227
2.202
2.202
2.202
2.202
2.202
2.202
2.399
2.433
2.150
2.249
2.227
2.347
2.109
2.150
2.150
2.363
2.516
2.427
2.211
2.494
2.322
2.322
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Q9NPG4
Q96QU1
Q96JQ0
O14917
Q9HCL0
Q8TAB3
Q8N6Y1
O60245
O95206
Q9HC56
P07949
P08922
P01135
P16109
Q14242
Q96KV6
P58550
B8ZZ34
A6NJW9
Q5T292
Q8N1Y9
O60894
O60895
O60896
P04626
P21860
Q15303
P36888
P18433
P23467
P08575
P23468
P23469
Q12913
P10586
P23470
Q9HD43
Q15262
P28827
Q92932
Q16827
Q15256
Q13332
O14522
Q92729
P23471
Protocadherin-12
Protocadherin-15
Protocadherin-16
Protocadherin-17
Protocadherin-18
Protocadherin-19
Protocadherin-20
Protocadherin-7
Protocadherin-8
Protocadherin-9
Proto-oncogene tyrosine-protein kin...
Proto-oncogene tyrosine-protein kin...
Protransforming growth factor alpha
P-selectin
P-selectin glycoprotein ligand 1
Putative butyrophilin subfamily 2 m... 
Putative FXYD domain-containing ion... 
Putative protein shisa-8
Putative T-cell surface glycoprotei... 
Putative uncharacterized protein C1...
Putative uncharacterized protein FL...
Receptor activity-modifying protein... 
Receptor activity-modifying protein... 
Receptor activity-modifying protein... 
Receptor tyrosine-protein kinase er...
Receptor tyrosine-protein kinase er...
Receptor tyrosine-protein kinase er...
Receptor-type tyrosine-protein kina...
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos...
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos...
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos...
256.06
290.79
249.37
226.77
277.40
244.35
164.85
286.19
260.24
279.91
237.23
220.08
302.08
166.94
272.80
247.69
138.49
165.69
228.45
174.89
211.71
217.15
233.89
230.54
288.28
205.43
257.73
227.61
294.97
231.79
265.27
299.99
270.29
201.67
278.24
288.70
262.76
298.74
298.74
223.01
249.78
261.50
276.56
243.51
253.97
292.46
2.666
2.407
2.070
2.629
2.710
2.635
3.010
2.432
2.625
2.447
2.594
2.642
2.782
2.842
2.404
2.653
3.063
2.820
2.396
3.067
2.439
2.579
2.855
2.709
2.385
2.725
2.611
2.734
2.598
2.764
2.500
2.793
1.698
2.609
2.479
2.931
2.156
2.362
2.362
2.718
2.411
2.725
2.567
2.628
2.398
3.008
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Q8IUW5
O75787
Q02846
P51841
Q6H3X3
Q9ULK6
Q9Y6N7
Q9HCK4
Q96MS0
Q14162
Q96GP6
Q86VB7
Q9NR16
Q8WVN6
Q13018
Q9BYH1
Q6UXD5
Q53EL9
Q9H3S1
Q9NPR2
Q9C0C4
Q92854
O95754
Q9NTN9
Q13591
Q9H2E6
Q9H3T3
Q9H3T2
Q8NFY4
Q6UWB4
P37023
Q96LC7
Q96RL6
Q96PQ1
Q08ET2
Q6ZMC9
A6NMB1
O15389
O43699
Q9Y286
Q9NYZ4
Q9Y336
Q9BZZ2
Q04900
Q13291
Q9Y3P8
RELT-like protein 1
Renin receptor
Retinal guanylyl cyclase 1
Retinal guanylyl cyclase 2
Retinoic acid early transcript 1G p... 
RING finger protein 150
Roundabout homolog 1
Roundabout homolog 2
Roundabout homolog 3
Scavenger receptor class F member 1
Scavenger receptor class F member 2
Scavenger receptor cysteine-rich ty...
Scavenger receptor cysteine-rich ty...
Secreted and transmembrane protein ... 
Secretory phospholipase A2 receptor 
Seizure 6-like protein
Seizure 6-like protein 2
Seizure protein 6 homolog 
Semaphorin-4A 
Semaphorin-4B 
Semaphorin-4C 
Semaphorin-4D 
Semaphorin-4F 
Semaphorin-4G 
Semaphorin-5A 
Semaphorin-6A 
Semaphorin-6B 
Semaphorin-6C 
Semaphorin-6D
Serine protease 55
Serine/threonine-protein kinase rec...
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialic acid-binding Ig-like lectin ... 
Sialoadhesin
Sialomucin core protein 24
Signaling lymphocytic activation mo... 
Signaling threshold-regulating tran...
204.60
216.31
197.48
209.62
204.60
247.69
201.25
171.54
170.71
212.97
219.24
272.38
267.36
217.57
249.37
212.55
215.06
217.57
240.16
243.51
276.14
216.31
192.46
207.53
176.15
226.35
179.49
191.63
234.30
47.70
245.18
227.19
196.23
206.27
97.49
206.27
232.21
243.93
192.88
220.08
206.69
212.97
233.47
209.20
225.94
189.95
2.921
2.936
2.602
3.044
2.571
2.499
2.852
2.892
2.096
2.532
2.331
2.211
1.982
2.599
2.741
2.669
2.682
2.738
2.549
2.362
2.069
2.056
2.344
2.583
2.995
2.761
2.247
2.221
2.494
2.991
2.318
2.499
2.559
2.669
2.946
2.013
2.815
2.649
2.957
2.675
2.707
2.599
1.868
2.599
2.833
2.644
72
 
 
O00241
Q5TFQ8
Q5JXA9
Q9P1W8
Q9UIB8
Q96DU3
Q9NQ25
Q9P0V8
Q96A28
Q96PX8
Q9H156
O94933
Q8IW52
O94991
Q9H5Y7
Q9BQ49
A6NGZ8
Q07699
O60939
Q9NY72
Q8IWT1
Q99523
Q92673
Q9HBV2
W5XKT8
Q9NY15
Q8WWQ8
Q13586
Q9P246
Q6UWL2
Q9UGT4
Q5VX71
O60279
Q92537
Q9UQF0
P18827
P34741
O75056
P31431
P09564
P30203
Q96H15
Q495A1
P06729
P06126
P29016
Signal-regulatory protein beta-1
Signal-regulatory protein beta-1 is... 
Signal-regulatory protein beta-2
Signal-regulatory protein gamma
SLAM family member 5
SLAM family member 6
SLAM family member 7
SLAM family member 8
SLAM family member 9
SLIT and NTRK-like protein 1
SLIT and NTRK-like protein 2
SLIT and NTRK-like protein 3
SLIT and NTRK-like protein 4
SLIT and NTRK-like protein 5
SLIT and NTRK-like protein 6
Small integral membrane protein 7
Small integral membrane protein 9
Sodium channel subunit beta-1
Sodium channel subunit beta-2
Sodium channel subunit beta-3
Sodium channel subunit beta-4
Sortilin
Sortilin-related receptor
Sperm acrosome membrane-associated ... 
Sperm acrosome membrane-associated ... 
Stabilin-1
Stabilin-2
Stromal interaction molecule 1
Stromal interaction molecule 2
Sushi domain-containing protein 1
Sushi domain-containing protein 2
Sushi domain-containing protein 4
Sushi domain-containing protein 5
Sushi domain-containing protein 6
Syncytin-1
Syndecan-1
Syndecan-2
Syndecan-3
Syndecan-4
T-cell antigen CD7
T-cell differentiation antigen CD6
T-cell immunoglobulin and mucin dom... 
T-cell immunoreceptor with Ig and I...
T-cell surface antigen CD2
T-cell surface glycoprotein CD1a
T-cell surface glycoprotein CD1b
199.16
206.69
214.64
148.53
251.04
273.22
265.68
223.84
230.12
224.26
243.93
245.60
292.04
253.13
261.08
186.19
227.61
197.48
252.30
202.09
276.56
268.61
247.27
310.87
176.15
179.49
198.32
145.18
134.31
194.56
238.07
208.36
245.18
242.25
184.93
220.08
295.81
234.72
300.41
218.40
240.16
233.89
239.32
251.88
246.44
233.05
2.790
2.764
2.548
3.088
2.097
2.458
1.796
2.477
2.591
2.589
2.437
2.252
2.374
2.480
2.721
2.792
2.911
3.084
2.460
2.805
2.265
2.800
2.535
2.074
2.589
2.136
2.404
3.237
3.080
2.864
2.424
2.710
2.720
2.407
2.492
2.566
2.427
2.435
2.554
2.502
2.404
2.537
2.684
2.964
2.469
2.833
73
 
 
P29017
P04234
P07766
P09693
P20963
P01730
P06127
P01732
P10966
P40200
B6A8C7
P10747
Q96GX1
Q6NUS6
Q9BZG2
P36897
P37173
Q96J42
Q9H3N1
Q9Y320
P07204
P40238
Q9NS62
Q9UPZ6
Q9C0I4
P07202
P13726
Q7L0X0
P33681
P42081
Q9HBG7
Q15399
Q9BXR5
O60603
O00206
O60602
Q9Y2C9
Q9NYK1
Q9NR97
Q9NR96
Q8IYR6
Q9UIK5
Q03167
O43493
Q6UXZ0
Q96BF3
T-cell surface glycoprotein CD1c
T-cell surface glycoprotein CD3 del... 
T-cell surface glycoprotein CD3 eps... 
T-cell surface glycoprotein CD3 gam... 
T-cell surface glycoprotein CD3 zet...
T-cell surface glycoprotein CD4
T-cell surface glycoprotein CD5
T-cell surface glycoprotein CD8 alp... 
T-cell surface glycoprotein CD8 bet... 
T-cell surface protein tactile
T-cell-interacting, activating rece...
T-cell-specific surface glycoprotei... 
Tectonic-2
Tectonic-3
Testicular acid phosphatase
TGF-beta receptor type-1
TGF-beta receptor type-2
Thioredoxin domain-containing prote...
Thioredoxin-related transmembrane p...
Thioredoxin-related transmembrane p...
Thrombomodulin
Thrombopoietin receptor
Thrombospondin type-1 domain-contai... 
Thrombospondin type-1 domain-contai... 
Thrombospondin type-1 domain-contai... 
Thyroid peroxidase
Tissue factor
TLR4 interactor with leucine rich r...
T-lymphocyte activation antigen CD8... 
T-lymphocyte activation antigen CD8... 
T-lymphocyte surface antigen Ly-9
Toll-like receptor 1
Toll-like receptor 10
Toll-like receptor 2
Toll-like receptor 4
Toll-like receptor 5
Toll-like receptor 6
Toll-like receptor 7
Toll-like receptor 8
Toll-like receptor 9
Tomoregulin-1
Tomoregulin-2
Transforming growth factor beta rec...
Trans-Golgi network integral membra...
Transmembrane and immunoglobulin do... 
Transmembrane and immunoglobulin do...
250.62
205.43
207.53
201.25
194.97
236.81
302.50
302.50
240.58
204.18
174.89
279.91
149.79
167.36
205.43
212.55
182.00
184.10
207.53
187.44
254.81
219.24
226.35
210.87
169.03
180.33
314.22
207.53
177.82
221.33
215.89
223.43
271.96
221.75
230.96
205.43
207.11
187.44
216.31
158.99
258.99
256.90
168.20
165.27
217.99
173.22
2.479
2.821
3.331
2.669
2.719
2.339
2.848
2.848
2.487
3.083
3.067
2.851
2.617
2.798
2.244
3.127
2.955
2.895
2.907
2.853
2.667
2.461
2.674
2.821
2.992
3.163
2.381
2.067
3.199
2.972
2.791
2.715
2.688
2.798
2.486
2.458
2.928
2.549
2.375
2.798
2.470
2.684
2.882
2.780
2.875
2.761
74
 
 
Q13445
O14668
O14669
Q9BZD7
Q9BZD6
Q14956
Q8NEW7
Q4V9L6
Q8N3G9
A2VDJ0
Q24JP5
Q14DG7
Q8N3T6
Q14C87
Q6IEE7
Q8IV31
Q6P9G4
Q8WZ59
A6NLX4
A2RRL7
Q86YD3
Q9BXS4
Q6P7N7
A2RUT3
Q9P0T7
Q6UXU6
Q3KNT9
Q86YW5
Q5T2D2
Q9NP99
Q9NZC2
Q13641
P0DKB5
O00220
O14763
Q9UBN6
Q9Y6Q6
Q9NP84
Q92956
P08138
Q9Y5U5
Q9NS68
Q969Z4
P19438
P20333
O75509
Transmembrane emp24 domain-containi... 
Transmembrane gamma-carboxyglutamic...
Transmembrane gamma-carboxyglutamic...
Transmembrane gamma-carboxyglutamic...
Transmembrane gamma-carboxyglutamic...
Transmembrane glycoprotein NMB 
Transmembrane inner ear expressed p... 
Transmembrane protein 119
Transmembrane protein 130
Transmembrane protein 131-like 
Transmembrane protein 132A 
Transmembrane protein 132B 
Transmembrane protein 132C 
Transmembrane protein 132D 
Transmembrane protein 132E 
Transmembrane protein 139
Transmembrane protein 154
Transmembrane protein 190
Transmembrane protein 210
Transmembrane protein 213
Transmembrane protein 25
Transmembrane protein 59
Transmembrane protein 81
Transmembrane protein 89
Transmembrane protein 9
Transmembrane protein 92
Transmembrane protein 95
Trem-like transcript 1 protein Trem-
like transcript 2 protein Triggering
receptor expressed on my... Triggering
receptor expressed on my...
Trophoblast glycoprotein
Trophoblast glycoprotein-like
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
190.37
242.25
197.90
267.36
222.59
18.41
224.68
257.32
186.19
190.37
253.55
240.58
220.50
220.50
269.45
162.76
291.21
156.48
244.76
176.15
183.26
184.93
209.20
113.39
233.05
247.27
222.17
254.39
211.29
190.37
223.01
244.76
238.07
307.52
254.81
284.09
254.39
176.15
191.63
221.75
207.53
256.90
230.54
250.62
274.47
273.63
2.728
2.505
2.646
2.822
2.535
3.427
2.707
2.702
2.897
2.723
2.383
2.558
2.821
2.821
2.444
2.561
2.105
2.828
2.686
2.955
2.705
3.101
2.584
3.414
2.800
2.653
2.332
2.293
2.669
2.594
2.377
2.397
2.438
2.512
2.512
2.531
2.435
2.564
2.841
2.903
2.599
2.553
2.972
2.548
3.084
2.543
75
 
 
Q93038
P36941
P43489
P25942
P25445
P28908
Q07011
Q9UNE0
Q8NBR0
P09758
O43914
Q12866
P35590
Q06418
P30530
P34925
Q01974
P78324
Q9Y4X1
Q6UWM9
Q6NUS8
Q3SY77
Q96F05
Q6NUJ2
Q86TY3
Q8NEA5
Q5SY80
Q5JRM2
Q3SXP7
Q8IYS2
Q6UXG2
A8MWY0
Q5DID0
B0FP48
O75445
P19320
P17948
P35968
P35916
Q6EMK4
P98155
Q96AW1
P54289
Q9NY47
Q8IZS8
Q7Z3S7
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor protein p53-inducible protein... 
Tumor-associated calcium signal tra...
TYRO protein tyrosine kinase-bindin...
Tyrosine-protein kinase Mer
Tyrosine-protein kinase receptor Ti...
Tyrosine-protein kinase receptor TY... 
Tyrosine-protein kinase receptor UF...
Tyrosine-protein kinase RYK
Tyrosine-protein kinase transmembra...
Tyrosine-protein phosphatase non-re... 
UDP-glucuronosyltransferase 2A1
UDP-glucuronosyltransferase 2A3
UDP-glucuronosyltransferase 3A1
UDP-glucuronosyltransferase 3A2
Uncharacterized protein C11orf24
Uncharacterized protein C11orf87
Uncharacterized protein C14orf37
Uncharacterized protein C19orf18
Uncharacterized protein C1orf101
Uncharacterized protein CXorf66
Uncharacterized protein KIAA1644
Uncharacterized protein KIAA2013
UPF0577 protein KIAA1324
UPF0577 protein KIAA1324-like
Uromodulin-like 1
Uroplakin-3b-like protein
Usherin
Vascular cell adhesion protein 1
Vascular endothelial growth factor ... 
Vascular endothelial growth factor ... 
Vascular endothelial growth factor ... 
Vasorin
Very low-density lipoprotein recept... 
Vesicular, overexpressed in cancer,...
Voltage-dependent calcium channel s... 
Voltage-dependent calcium channel s... 
Voltage-dependent calcium channel s... 
Voltage-dependent calcium channel s...
184.93
216.73
225.10
304.60
171.96
261.92
247.69
263.59
191.63
304.60
212.97
188.70
228.03
225.52
254.81
267.36
235.56
250.62
208.36
197.07
156.48
161.50
273.22
259.41
184.93
193.30
251.04
253.97
210.46
176.15
140.58
161.92
269.87
290.37
269.45
203.34
207.53
267.36
263.59
216.31
179.91
169.03
122.17
156.06
144.77
116.73
2.739
2.628
2.236
2.282
2.461
2.849
2.380
2.380
2.345
2.278
2.739
2.630
2.868
2.453
2.402
3.108
2.680
2.689
2.568
2.602
2.916
2.512
2.065
2.338
2.805
2.895
2.376
2.630
2.607
2.459
3.163
2.761
2.381
2.244
2.357
2.859
2.455
2.630
2.489
1.977
2.863
2.756
2.995
2.375
2.602
2.678
76
 
 
Q86XK7
Q8N0Z9
Q86VR7
Q96IQ7
Q9Y279
Q5VU13
A6NLU5
Q8IW00
A8MXK1
Q7Z7D3
Q9H7M9
Q5VU97
Q9NP60
P60852
Q05996
P21754
Q12836
Q8TCW7
Q9Y493
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con...
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con... 
V-set and transmembrane domain-cont... 
V-set and transmembrane domain-cont... 
V-set and transmembrane domain-cont... 
V-set domain-containing T-cell acti...
V-type immunoglobulin domain-contai... 
VWFA and cache domain-containing pr...
X-linked interleukin-1 receptor acc...
Zona pellucida sperm-binding protei... 
Zona pellucida sperm-binding protei... 
Zona pellucida sperm-binding protei... 
Zona pellucida sperm-binding protei... 
Zona pellucida-like domain-containi... 
Zonadhesin
224.26
230.54
246.02
236.81
242.25
219.24
116.32
263.17
241.00
136.82
233.47
187.44
222.17
231.38
172.38
239.74
174.05
186.19
241.00
2.475
2.452
2.167
2.477
2.911
2.756
2.434
2.819
2.476
2.947
2.718
2.946
2.536
2.261
2.514
2.432
2.813
2.841
2.218
77
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Uniprot
ID
 
Protein Name
Hydrophobic 
Energy
(kJ/mol)
Shannon
Entropy
(bits)
P08195
Q9HDC9
P28907
P15144
P07306
P07307
Q9Y5Q5
P21854
Q5T4J0
Q6ZNI0
Q16585
Q6UWU4
Q10589
Q9UIR0
P21964
Q9NNX6
P29965
P32970
Q5TAT6
Q9UMD9
Q86Y22
Q9BXS0
Q5KU26
Q8NC01
Q9P126
Q8IUN9
Q5QGZ9
Q2HXU8
Q6ZS10
Q6UVW9
Q92478
Q9UHP7
Q9UMR7
Q8WTT0
Q8WXI8
Q9ULY5
Q8N1N0
Q6UXB4
Q9UJ71
Q9H2X3
Q9NY25
4F2 cell-surface antigen heavy chai... 
Adipocyte plasma membrane-associate... 
ADP-ribosyl cyclase/cyclic ADP-ribo... 
Aminopeptidase N
Asialoglycoprotein receptor 1
Asialoglycoprotein receptor 2
Atrial natriuretic peptide-converti... 
B-cell differentiation antigen CD72
Beta-1,3-galactosyl-O-glycosyl-glyc...
Beta-1,3-galactosyl-O-glycosyl-glyc...
Beta-sarcoglycan
Bombesin receptor-activated protein... 
Bone marrow stromal antigen 2
Butyrophilin-like protein 2
Catechol O-methyltransferase
CD209 antigen
CD40 ligand
CD70 antigen
Collagen alpha-1(XIII) chain 
Collagen alpha-1(XVII) chain 
Collagen alpha-1(XXIII) chain 
Collagen alpha-1(XXV) chain 
Collectin-12
C-type lectin domain family 1 membe... 
C-type lectin domain family 1 membe... 
C-type lectin domain family 10 memb... 
C-type lectin domain family 12 memb... 
C-type lectin domain family 12 memb... 
C-type lectin domain family 17, mem... 
C-type lectin domain family 2 membe... 
C-type lectin domain family 2 membe... 
C-type lectin domain family 2 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 5 membe...
223.84
197.07
261.92
227.19
245.18
197.90
301.67
230.54
195.81
169.03
294.97
198.32
302.50
115.06
290.37
151.46
200.83
238.91
159.41
233.05
209.20
222.17
228.03
235.14
246.86
233.89
235.14
216.31
215.89
223.43
194.56
234.30
262.76
166.10
241.42
154.39
200.00
240.58
214.64
238.91
231.79
2.718
2.604
2.527
2.955
2.108
3.010
2.053
2.298
2.915
3.131
2.470
2.946
2.510
3.264
1.417
2.503
3.288
2.475
2.161
1.875
2.424
2.529
2.910
2.429
2.725
2.486
2.620
2.606
2.606
2.944
2.669
3.142
2.332
2.941
2.623
3.313
2.539
2.659
2.695
2.642
3.046
79
 
 
Q6EIG7
Q9BXN2
Q6UXN8
Q8IZS7
Q07065
Q92629
P42658
P27487
O75923
Q07108
Q92838
P22413
O14638
P42892
P98073
Q8N539
P36269
Q6P531
Q9UJ14
P19440
Q13326
Q6ZMI3
Q04609
Q07075
P04233
Q8N608
Q58DX5
Q01628
P23276
Q12918
Q9NZS2
D3W0D1
Q96E93
Q5H943
Q9UIQ6
P06734
Q06643
Q9UEW3
P21757
Q8IX19
Q9BY79
Q16853
P08910
Q9BV23
Q9NZM1
Q9Y3Q0
C-type lectin domain family 6 membe... 
C-type lectin domain family 7 membe...
C-type lectin domain family 9 membe... 
C-type lectin-like domain family 1
Cytoskeleton-associated protein 4
Delta-sarcoglycan
Dipeptidyl aminopeptidase-like prot... 
Dipeptidyl peptidase 4
Dysferlin
Early activation antigen CD69
Ectodysplasin-A
Ectonucleotide pyrophosphatase/phos... 
Ectonucleotide pyrophosphatase/phos... 
Endothelin-converting enzyme 1
Enteropeptidase
Fibrinogen C domain-containing prot... 
Gamma-glutamyltransferase 5
Gamma-glutamyltransferase 6
Gamma-glutamyltransferase 7
Gamma-glutamyltranspeptidase 1
Gamma-sarcoglycan
Gliomedin
Glutamate carboxypeptidase 2
Glutamyl aminopeptidase
HLA class II histocompatibility ant... 
Inactive dipeptidyl peptidase 10
Inactive N-acetylated-alpha-linked ... 
Interferon-induced transmembrane pr...
Kell blood group glycoprotein
Killer cell lectin-like receptor su... 
Killer cell lectin-like receptor su... 
Killer cell lectin-like receptor su... 
Killer cell lectin-like receptor su... 
Kita-kyushu lung cancer antigen 1
Leucyl-cystinyl aminopeptidase
Low affinity immunoglobulin epsilon...
Lymphotoxin-beta
Macrophage receptor MARCO
Macrophage scavenger receptor types... 
Mast cell-expressed membrane protei... 
Membrane frizzled-related protein 
Membrane primary amine oxidase 
Monoacylglycerol lipase ABHD2
Monoacylglycerol lipase ABHD6
Myoferlin
N-acetylated-alpha-linked acidic di...
194.97
299.57
210.46
176.15
160.67
247.27
278.65
243.51
295.39
263.17
178.24
220.08
34.73
262.76
240.58
241.00
267.36
165.69
190.79
295.81
269.03
172.80
207.53
250.62
134.31
267.78
201.67
262.76
228.03
212.13
171.96
229.28
192.46
134.31
273.22
184.10
301.25
222.59
283.68
261.50
270.29
308.78
176.56
204.18
272.38
195.81
2.987
2.358
3.214
3.273
2.951
2.790
2.529
2.347
2.070
2.851
2.617
2.797
2.847
2.256
3.411
2.256
2.189
2.810
2.834
2.178
2.426
2.659
2.690
2.373
3.046
2.715
3.042
2.414
2.822
2.643
2.553
2.892
2.908
3.081
2.737
2.720
0.280
2.856
2.509
2.856
1.963
2.428
2.665
2.778
2.486
3.205
80
 
 
Q9UQQ1
Q13241
P08473
O95502
Q07837
P26715
P26717
P26718
Q07444
O43908
Q9HC10
P78380
P78562
O15162
Q9NRY7
Q9NRY6
Q9NRQ2
Q9BX97
P51164
Q12884
Q6UWH4
Q9H0X4
A6NGU5
P0C7V7
P46695
Q6AZY7
Q6ZMJ2
P05981
A6NLE4
P05026
P14415
P54709
Q8IXA5
Q9Y5Y6
Q9H7V2
Q9H2S6
Q9UKU6
P55073
P02786
Q9UP52
Q6ZMR5
Q86T26
O60235
Q9UL52
Q6ZWK6
Q9BYE2
N-acetylated-alpha-linked acidic di... 
Natural killer cells antigen CD94
Neprilysin
Neuronal pentraxin receptor
Neutral and basic amino acid transp... 
NKG2-A/NKG2-B type II integral memb... 
NKG2-C type II integral membrane pr...
NKG2-D type II integral membrane pr...
NKG2-E type II integral membrane pr...
NKG2-F type II integral membrane pr...
Otoferlin
Oxidized low-density lipoprotein re...
Phosphate-regulating neutral endope...
Phospholipid scramblase 1
Phospholipid scramblase 2
Phospholipid scramblase 3
Phospholipid scramblase 4
Plasmalemma vesicle-associated prot... 
Potassium-transporting ATPase subun... 
Prolyl endopeptidase FAP
Protein FAM198B 
Protein FAM234A
Putative gamma-glutamyltranspeptida...
Putative signal peptidase complex c...
Radiation-inducible immediate-early...
Scavenger receptor class A member 3
Scavenger receptor class A member 5
Serine protease hepsin
Small integral membrane protein 23
Sodium/potassium-transporting ATPas... 
Sodium/potassium-transporting ATPas... 
Sodium/potassium-transporting ATPas... 
Sperm acrosome membrane-associated ... 
Suppressor of tumorigenicity 14 pro...
Synapse differentiation-inducing ge...
Tenomodulin
Thyrotropin-releasing hormone-degra...
Thyroxine 5-deiodinase
Transferrin receptor protein 1
Transferrin receptor protein 2
Transmembrane protease serine 11A 
Transmembrane protease serine 11B
Transmembrane protease serine 11D 
Transmembrane protease serine 11E 
Transmembrane protease serine 11F
Transmembrane protease serine 13
186.19
184.10
233.05
247.27
239.32
299.57
217.15
201.25
217.15
223.43
248.11
214.64
221.75
134.72
117.57
118.83
111.71
251.46
151.46
219.24
141.00
259.41
295.81
87.45
139.33
261.08
267.78
189.54
142.26
248.95
199.16
184.10
176.56
274.47
153.13
197.48
250.20
182.42
166.94
187.02
253.55
220.50
261.50
265.68
222.59
273.22
2.281
2.527
2.794
2.774
2.756
2.730
3.029
2.737
3.029
2.773
1.345
2.725
2.774
3.102
3.293
3.293
3.102
2.648
3.273
3.106
3.192
2.529
2.178
3.503
2.940
2.392
2.563
2.720
2.814
3.285
3.271
2.815
0.621
2.280
3.195
3.066
2.351
3.038
2.987
2.820
2.684
2.856
2.725
2.810
2.761
2.433
81
 
 
O15393
P57727
Q9NRS4
Q9H3S3
Q8IU80
Q7RTY8
Q7Z410
Q9Y2B1
P01375
P50591
O14788
O43508
Q9Y275
O43557
O95150
Q9UNG2
P23510
P48023
P32971
P41273
Q6NSJ0
Q96LD1
Transmembrane protease serine 2
Transmembrane protease serine 3
Transmembrane protease serine 4
Transmembrane protease serine 5
Transmembrane protease serine 6
Transmembrane protease serine 7
Transmembrane protease serine 9
Transmembrane protein 5
Tumor necrosis factor
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Uncharacterized family 31 glucosida...
Zeta-sarcoglycan
186.19
254.39
266.94
178.66
227.61
242.67
212.97
141.84
182.84
195.81
195.39
224.68
199.58
170.29
187.44
227.19
228.86
253.55
225.10
240.16
206.27
227.19
2.623
2.207
2.242
2.296
2.486
2.665
2.720
3.082
3.154
3.078
2.910
1.991
2.642
2.506
2.528
2.739
3.180
2.554
2.901
2.200
2.599
2.915
 
